<SEC-DOCUMENT>0001144204-17-063359.txt : 20171212
<SEC-HEADER>0001144204-17-063359.hdr.sgml : 20171212
<ACCEPTANCE-DATETIME>20171212170040
ACCESSION NUMBER:		0001144204-17-063359
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		6
CONFORMED PERIOD OF REPORT:	20171206
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20171212
DATE AS OF CHANGE:		20171212

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Cyclacel Pharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0001130166
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				911766850
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-50626
		FILM NUMBER:		171252352

	BUSINESS ADDRESS:	
		STREET 1:		200 CONNELL DRIVE
		STREET 2:		SUITE 1500
		CITY:			BERKELEY HEIGHTS
		STATE:			NJ
		ZIP:			07922
		BUSINESS PHONE:		908-517-7330

	MAIL ADDRESS:	
		STREET 1:		200 CONNELL DRIVE
		STREET 2:		SUITE 1500
		CITY:			BERKELEY HEIGHTS
		STATE:			NJ
		ZIP:			07922

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	XCYTE THERAPIES INC
		DATE OF NAME CHANGE:	20001218
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>tv481140_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Washington, D.C. 20549 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM 8-K </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CURRENT REPORT </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Pursuant to Section 13 or 15(d) </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>of the Securities Exchange Act of 1934
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Date of Report (Date of earliest event
reported): December 6, 2017</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CYCLACEL PHARMACEUTICALS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Exact name of registrant as specified
in its charter) </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR>
    <TD STYLE="text-align: center; width: 33%"><FONT STYLE="font-size: 10pt"><B>Delaware</B></FONT></TD>
    <TD STYLE="text-align: center; width: 34%"><FONT STYLE="font-size: 10pt"><B>0-50626</B></FONT></TD>
    <TD STYLE="text-align: center; width: 33%"><FONT STYLE="font-size: 10pt"><B>91-1707622</B></FONT></TD></TR>
<TR>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt"><B>(State or other jurisdiction</B></FONT><BR>
<FONT STYLE="font-size: 10pt"><B>of incorporation)</B></FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt"><B>(Commission File Number)</B></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt"><B>(IRS Employer</B></FONT><BR>
<FONT STYLE="font-size: 10pt"><B>Identification No.)</B></FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>200 Connell Drive, Suite 1500<BR>
Berkeley Heights, NJ 07922<BR>
(Address of principal executive offices and zip code) </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Registrant&rsquo;s telephone number,
including area code: (908) 517-7330</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 90%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="text-align: center; border-bottom: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 100%; text-align: center"><B>(Former Name or Former Address, if Changed
Since Last Report)</B></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Check the appropriate box below if the Form 8-K filing is
intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (<I>see </I>General
Instruction A.2. below): </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uml;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</B></FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uml;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Soliciting material pursuant
to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</B></FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uml;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Pre-commencement communications
pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</B></FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uml;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Pre-commencement communications
pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</B></FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><B>Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (&sect;230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (&sect;240.12b-2 of this chapter).&nbsp;<FONT STYLE="font-family: Wingdings">&uml;</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><B>If an emerging growth company, indicate by check mark if
the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act.&nbsp;<FONT STYLE="font-family: Wingdings">&uml;</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.75in; text-align: left"><FONT STYLE="font-size: 10pt"><B>Item&nbsp;5.02</B></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Departure of Directors
or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.</B></FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On December
6, 2017, the Board of Directors (the &ldquo;<B>Board</B>&rdquo;) of Cyclacel Pharmaceuticals, Inc. (the &ldquo;<B>Company</B>&rdquo;),
at the recommendation of the Company&rsquo;s Compensation and Organization Development Committee (the &ldquo;<B>Committee</B>&rdquo;),
approved the renewal of the employment agreements (each, an &ldquo;<B>Employment Agreement</B>&rdquo;) of Spiro Rombotis, the President
and Chief Executive Officer of the Company, and Paul McBarron, the Executive Vice President-Finance, Chief Financial Officer and
Chief Operating Officer of the Company, such renewals to be effective from January 1, 2017 through January 1, 2019.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Employment Agreement for Spiro Rombotis</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to Mr. Rombotis&rsquo;
Employment Agreement, Mr.&nbsp;Rombotis&rsquo; initial annual base salary remains unchanged at $530,553, which may be increased
by the Committee from time to time, and he may also be eligible for a yearly incentive cash bonus based on a percentage of his
then current base salary if he meets certain corporate and individual performance criteria set by the Committee at the beginning
of each year of employment, subject to the approval of the Board. The Agreement also provides for reimbursement of reasonable and
necessary expenses incurred by Mr.&nbsp;Rombotis in connection with the performance of his services. In addition, Mr.&nbsp;Rombotis
is entitled to employment benefits in accordance with the Company&rsquo;s benefit policies in effect from time to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Agreement also
provides for certain severance arrangements for Mr.&nbsp;Rombotis. In the event that Mr.&nbsp;Rombotis&rsquo; employment is terminated
without &ldquo;cause,&rdquo; other than termination for a &ldquo;change of control&rdquo; (each as defined in the Agreement), the
Company will be required to pay Mr.&nbsp;Rombotis (i) all accrued but unpaid compensation up to the time of such termination; (ii)
for a period of twelve months following such termination, severance payments in the form of continuation of his base salary as
in effect immediately prior to such termination, including coverage of his medical care and life insurance, unless Mr.&nbsp;Rombotis
obtains substitute coverage (the &ldquo;<B>Severance Payments</B>&rdquo;); and (iii) six months&rsquo; accelerated vesting of any
options held by Mr.&nbsp;Rombotis. In the event that Mr.&nbsp;Rombotis&rsquo; employment is terminated within six months following
a &ldquo;change in control&rdquo; event, Mr.&nbsp;Rombotis will be entitled to (i) all accrued but unpaid compensation up to the
time of such termination; (ii) Severance Payments for a period of 24 months; (iii) out-of-pocket expenses reasonably incurred by
Mr. Rombotis in connection with his and his family&rsquo;s relocation to London; and (iv) 18 months&rsquo; accelerated vesting
of any options held by him. In the event of termination due to his death or disability, the Company is required to pay Mr.&nbsp;Rombotis
(or his estate, as the case may be) (i) all accrued but unpaid compensation up to the time of such termination; (ii) Severance
Payments for a period of twelve months; and (iii) he will be entitled to twelve months&rsquo; accelerated vesting of his options.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, Mr.&nbsp;Rombotis
also agreed to certain confidentiality and assignment of inventions obligations and will be subject to certain non-competition
obligations for a period of one year following termination of his employment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Employment Agreement for Paul McBarron</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to Mr. McBarron&rsquo;s
Employment Agreement, Mr.&nbsp;McBarron&rsquo;s initial annual base salary remains unchanged at &pound;208,859, which may be increased
by the Committee from time to time, and he may also be eligible for a yearly incentive cash bonus based on a percentage of his
then current base salary if he meets certain corporate and individual performance criteria set by the Committee at the beginning
of each year of employment, subject to the approval of the Board. The Agreement also provides for reimbursement of reasonable and
necessary expenses incurred by Mr.&nbsp;McBarron in connection with the performance of his services. In addition, Mr.&nbsp;McBarron
is entitled to employment benefits in accordance with the Company&rsquo;s benefit policies in effect from time to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Agreement also
provides for certain severance arrangements for Mr.&nbsp;McBarron. In the event that Mr.&nbsp;McBarron&rsquo;s employment is terminated
without &ldquo;cause,&rdquo; other than termination for a &ldquo;change of control&rdquo; (each as defined in the Agreement), the
Company will be required to pay Mr.&nbsp;McBarron (i) all accrued but unpaid compensation up to the time of such termination; (ii)
Severance Payments for a period of twelve months following such termination; and (iii) six months&rsquo; accelerated vesting of
any options held by Mr.&nbsp;McBarron. In the event that Mr.&nbsp;McBarron&rsquo;s employment is terminated within six months following
a &ldquo;change in control&rdquo; event, Mr.&nbsp;McBarron will be entitled to (i) all accrued but unpaid compensation up to the
time of such termination; (ii) Severance Payments for a period of 12 months; and (iii) 18 months&rsquo; accelerated vesting of
any options held by him. In the event of termination due to his death or disability, the Company is required to pay Mr.&nbsp;McBarron
(or his estate, as the case may be) (i) all accrued but unpaid compensation up to the time of such termination; (ii) Severance
Payments for a period of twelve months; and (iii) he will be entitled to twelve months&rsquo; accelerated vesting of his options.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, Mr.&nbsp;McBarron
agreed to certain confidentiality and assignment of inventions obligations and will be subject to certain non-competition obligations
for a period of one year following termination of his employment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Mr. McBarron&rsquo;s
Agreement also contains certain provisions to assure compliance under the laws of the United Kingdom, Mr. McBarron&rsquo;s place
of employment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The foregoing descriptions
of the Employment Agreements do not purport to be complete and are qualified in their entirety by reference to the Employment Agreements
filed as Exhibits 10.1 and 10.2 to this Current Report on Form 8-K, and are incorporated herein by reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.75in; text-align: left"><FONT STYLE="font-size: 10pt"><B>Item&nbsp;8.01</B></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Other Events.</B></FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Dividend on 6% Convertible Exchangeable
Preferred Stock</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">On December 6, 2017, the Board declared
a quarterly cash dividend in the amount of $0.15 per share on the Company&rsquo;s 6% Convertible Exchangeable Preferred Stock (&ldquo;<B>Preferred
Stock</B>&rdquo;). The cash dividend will be payable on February 1, 2018 to the holders of record of the Preferred Stock as of
the close of business on January 12, 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">The Board considered numerous factors in
determining whether to declare the quarterly dividend, including the requisite financial analysis and determination of a surplus.
While the Board will analyze the advisability of the declaration of dividends in future quarters, there is no assurance that future
quarterly dividends will be declared.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;<U>Press Release</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">On December 12, 2017, Cyclacel <FONT STYLE="background-color: white">Pharmaceuticals,
Inc. issued a press release announcing the presentation of results from its pivotal Phase 3 SEAMLESS study in elderly patients
aged 70 years or older with newly diagnosed acute myeloid leukemia (AML), who are not candidates for or have refused intensive
induction chemotherapy. A copy of the press release is attached as Exhibit&nbsp;99.1 to this Current Report on Form 8-K, and the
information contained therein is incorporated herein by reference.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.75in; text-align: left"><FONT STYLE="font-size: 10pt"><B>Item&nbsp;9.01.</B></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Financial Statements and
Exhibits.</B></FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(d)&nbsp;&nbsp;&nbsp; Exhibits.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 10%; border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt"><B>Exhibit</B>&nbsp;<B>No.</B></FONT></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 88%; border-bottom: black 1pt solid; text-align: center; vertical-align: bottom"><FONT STYLE="font-size: 10pt"><B>Document</B></FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding-left: 8.65pt; text-indent: -8.65pt"><A HREF="tv481140_ex10-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">10.1</FONT></A></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><A HREF="tv481140_ex10-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Employment Agreement between Cyclacel Pharmaceuticals, Inc. and Spiro Rombotis</FONT></A></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding-left: 8.65pt; text-indent: -8.65pt"><A HREF="tv481140_ex10-2.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">10.2</FONT></A></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><A HREF="tv481140_ex10-2.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Employment Agreement between Cyclacel Pharmaceuticals, Inc. and Paul McBarron</FONT></A></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding-left: 8.65pt; text-indent: -8.65pt"><A HREF="tv481140_ex99-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">99.1</FONT></A></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><A HREF="tv481140_ex99-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Press release, dated December 12, 2017</FONT></A></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the requirements
of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned
thereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt"><B>CYCLACEL PHARMACEUTICALS, INC.</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 65%">&nbsp;</TD>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 30%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">/s/ Paul McBarron</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD NOWRAP><FONT STYLE="font-size: 10pt">Name:</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Paul McBarron</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
    <TD NOWRAP><FONT STYLE="font-size: 10pt">Executive Vice President&mdash;Finance, Chief Financial Officer and Chief Operating
Officer</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Date: December 12, 2017</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 5; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>tv481140_ex10-1.htm
<DESCRIPTION>EXHIBIT 10.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 10.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B><I>EXECUTION COPY</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EMPLOYMENT AGREEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>THIS EMPLOYMENT
AGREEMENT</B> (&ldquo;Agreement&rdquo;) is made as of January 1, 2017 by and between Cyclacel Pharmaceuticals, Inc., a Delaware
corporation, (&ldquo;Company&rdquo;) and Spiro Rombotis (&ldquo;the Executive&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>WHEREAS, </B>Company
and the Executive were parties to an Employment Agreement dated January 1, 2014, which expires by its terms on January 1, 2017;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>WHEREAS</B>, the
Company and the Executive mutually extended the term of the Employment Agreement dated January 1, 2014 through December 31, 2017;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>WHEREAS</B>, Company
desires to continue to retain the Executive&rsquo;s services as its President and Chief Executive Officer; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>WHEREAS</B>, Company
and the Executive are desirous of agreeing the terms and conditions of the Executive&rsquo;s employment with the Company as set
forth herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>NOW, THEREFORE</B>,
in consideration of the foregoing and the mutual covenants and conditions herein contained, the parties hereby agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><B><U>Employment</U></B>.
Company hereby employs the Executive and the Executive accepts such employment according to the terms and conditions set forth
in this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><B><U>Term</U></B>.
Except for earlier termination as hereinafter provided for, the term of the Executive&rsquo;s employment hereunder shall be for
a period commencing on January 1, 2017 (&ldquo;Commencement Date&rdquo;) and continuing through January 1, 2019; the second anniversary
of the Commencement Date. Notwithstanding the foregoing, the Executive&rsquo;s employment by the Company hereunder may be earlier
terminated, subject to Section 9 hereof, upon the occurrence of any one of the following events: (i) the Company&rsquo;s decision
to terminate the Executive, (ii) the Executive&rsquo;s decision to voluntarily resign or retire at any time or (iii) the parties&rsquo;
mutual agreement in writing to terminate the Executive&rsquo;s employment hereunder at any time. The period of time between the
Commencement Date and termination of the Executive&rsquo;s employment hereunder shall be referred to herein as the &ldquo;Employment
Period&rdquo;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><B><U>Position
and Services.</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Executive will hold the position of President and Chief Executive Officer of the Company. The Executive will report directly to
the Board of Directors of the Company (the &ldquo;Board&rdquo;) and shall have such duties, responsibilities and authority with
respect to such positions as are set forth in the Bylaws of the Company, which duties and responsibilities shall in all events
include, but not be limited to, overall management responsibility for the operations and administration of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Executive will be expected to be in the full-time employment of the Company, to devote substantially all of his business time,
attention and efforts to the performance of his duties hereunder. Notwithstanding the foregoing, the Executive may make and manage
personal business investments of his choice and serve in any capacity with any civic, educational or charitable organization, or
any trade association, without seeking or obtaining approval by the Board, provided such activities and service do not materially
interfere or conflict with the performance of his duties hereunder or violate the non-competition provisions of Section 12 hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Executive expressly agrees that during the Employment Period he will not be interested, directly or indirectly, in any form, fashion
or manner, as a partner, officer, director, advisor, employee, consultant, controlling stockholder or in any other form or capacity,
in any other business or company, except that he would not be prohibited by Section 12 hereof to serve as (a) member of one other
Board of Directors of a commercial organization, or (b) a member of one or more Boards of Directors or Trustees of a charitable
organization, as may, upon advance notice from the Executive be approved by the Board in its discretion after consideration of
possible conflicts, reputation(al) effects, time requirements and other interests of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Executive is currently serving as a
Class 2 director on the Company&rsquo;s Board for a term ending at the 2020 annual meeting. The Board will use its best efforts
to cause the nomination of the Executive thereafter for reelection as Class 2 director to the Board for successive terms, at every
time at which Class 2 directors are nominated to the stockholders for election, as long as the Executive serves as President and
Chief Executive Officer unless the Executive declines such nomination in writing to the Board. As with all members of the Board,
the Executive&rsquo;s continuation as a director requires election as a director by the stockholders whenever directors are to
be elected by the stockholders. If the Executive ceases to serve as President and Chief Executive Officer for any reason and the
Board thereafter requests that the Executive resigns as a director of the Board, the Executive shall immediately resign as a director.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><B><U>Base
Salary</U></B>. Company shall pay to the Executive an initial base salary at an annual rate of $530,553, subject to applicable
income and employment tax withholdings and all other required and authorized payroll deductions and withholdings. The Executive&rsquo;s
salary shall be payable at the same time and basis as the Company pays its payroll in general. Increases in the Executive&rsquo;s
annual base salary during the Employment Period may be effected from time to time based upon the review and approval of the Compensation
Committee of the Board (the &ldquo;Compensation Committee&rdquo;). During the Employment Period, the Executive&rsquo;s base salary
rate shall not be reduced below the initial base salary rate provided hereunder, nor below any increased base salary rate that
may be effected as provided hereunder, except if the Board, in response to exceptionally adverse business circumstances makes a
general temporary reduction in the compensation of the executives of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><B><U>Annual
Incentive Bonus</U></B>. In addition to the Executive&rsquo;s base salary as provided above, the Executive will be eligible for
an annual cash incentive bonus for each calendar year of the Employment Period. The bonus for which the Executive is eligible for
each such year will be based on a target percentage of the then current base salary, which target percentage shall be at least
50% of Executive&rsquo;s then current base salary. The determination of the amount of the annual cash incentive bonus will be based
upon the satisfaction of performance criteria established by the Compensation Committee in its discretion and upon consultation
with the Executive at the beginning of each year and subject to the approval of the Board. Depending on the Executives performance
against the performance criteria, the actual annual cash incentive bonus may be more, equal to or less than the target. Such performance
criteria will include corporate performance goals consistent with the Company&rsquo;s business plan for the year, as well as individual
objectives for the Executive&rsquo;s performance that may be separate from, but are consistent with, the Company&rsquo;s business
plan. The final determinations as to the actual corporate and individual performance against the pre-established goals and objectives,
and the amount of the bonus payout in relationship to such performance, will be made by the Compensation Committee in its sole
discretion. To the extent the Company awards the Executive a cash bonus, the bonus, if payable, shall be calculated and paid no
later than two and a half months following the later of the close of the calendar or Company fiscal year to which such bonus relates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><B><U>Executive
Benefits</U></B>. The Executive shall be entitled to receive employment benefits in accordance with the Company&rsquo;s benefit
policies in effect from time to time, including without limitation, 401(k) plan, medical, dental and life insurance, accidental
death, travel accident, short and long term disability insurance, profit sharing, long term incentive plans, and 15 working days
of paid vacation annually.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><B><U>Expenses</U></B>.
The Company shall reimburse the Executive for all reasonable and necessary expenses incurred by him in connection with the performance
of his services for the Company upon submission of expense reports and documentation in accordance with the Company&rsquo;s policies.
The Company may request additional documentation or a further explanation to substantiate any expense submitted for reimbursement,
and retains the discretion to approve or deny a request for reimbursement. If an expense reimbursement is not exempt from Section
409A of the Internal Revenue Code of 1986, as amended (the &ldquo;Code&rdquo;), any reimbursement in one calendar year shall not
affect the amount that may be reimbursed in any other calendar year and a reimbursement (or right thereto) may not be exchanged
or liquidated for another benefit or payment. Any expense reimbursements subject to Section 409A of the Code shall be made no later
than the end of the calendar year following the calendar year in which such business expense is incurred by the Executive.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><B><U>Indemnification</U></B>.
The Company shall indemnify the Executive in accordance with the Company&rsquo;s By-laws. The Company agrees that it will make
all commercially reasonable efforts to keep in full force and effect, for the duration of all applicable statute of limitations
periods, directors and officers liability insurance policies on terms at least as favorable to the Executive as those in effect
on the date hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><B><U>Termination</U></B>.
This Agreement does not grant the Executive any right or entitlement to be retained by the Company. In the event of termination
by the Company of the Executive&rsquo;s employment under the circumstances described below in this Section 9, the Executive shall
be entitled to the severance pay and benefits so specified.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Certain
Definitions</U>. For purposes of this Section 9, the following terms shall have the meanings given below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Termination
For Cause</U>. The employment of the Executive hereunder shall be deemed to have been terminated &ldquo;For Cause&rdquo; if the
Company shall have terminated the Executive as a result of any of the following: (A) any act committed by the Executive which shall
represent a breach in any material respect of any of the terms of this Agreement and which breach is not cured within 30 days of
receipt by the Executive of written notice from the Company of such breach; (B) improper conduct, consisting of any willful act
or omission with the intent of obtaining, to the material detriment of the Company, any benefit to which the Executive would not
otherwise be entitled; (C) gross negligence, consisting of wanton and reckless acts or omissions in the performance of the Executive&rsquo;s
duties to the material detriment of the Company; (D) addiction to drugs or chronic alcoholism or (E) any conviction of, or plea
of nolo contendere to, a crime (other than a traffic violation) under the laws of the United States, the United Kingdom, or any
of their respective political subdivisions, provided that the Executive receives a copy of a resolution duly adopted by a two thirds
majority affirmative vote of the membership of the Board excluding the Executive, at a meeting of the Board called and held for
such purpose after the Executive has been given reasonable notice of such meeting and has been given an opportunity, together with
his counsel, to be heard by the Board, finding that in the good faith opinion of the Board the Executive was guilty of the conduct
set forth and specifying the particulars thereof in detail.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Termination
Without Cause.</U> The employment of the Executive hereunder shall be deemed to have been terminated &ldquo;Without Cause&rdquo;
upon (A) termination of employment by the Company for any reason other than the reasons specified in <U>Section 9(a)(i)</U> hereof
as termination &ldquo;For Cause&rdquo; or the reasons specified in <U>Section 9(a)(iii)</U> hereof as termination because of the
Executive&rsquo;s Disability or Death, (B) termination of employment by the Company by virtue of the expiry of the Employment Period
on 1 January 2019 (or any specific extension thereof), unless the Company has offered in writing to renew the Executive&rsquo;s
employment after the expiry of the Employment Period on terms no less favorable than those provided in this Agreement (in which
case if the Executive does not accept renewal of his employment, the termination of his employment by virtue of the expiry of the
Employment Term will be deemed a resignation by the Executive), or (C) termination of employment by the Executive within 30 days
following a &ldquo;Constructive Termination&rdquo; event. For purposes hereof, the following shall constitute Constructive Termination
events: (1) any removal of the Executive from the position of President or Chief Executive Officer, (2) any material reduction
of the Executive&rsquo;s duties, responsibilities or authority, including any change in the Executive&rsquo;s positions as President
or Chief Executive Officer that results in such a reduction, (3) a material reduction by the Company in the Executive&rsquo;s base
salary in effect on the date hereof or as may be increased from time to time except if the Board in response to exceptional adverse
business circumstances makes a general temporary reduction in the compensation of the executives of the Company, (4) the Company
requiring the Executive without the Executive&rsquo;s express written consent to be based anywhere other than within 50 miles of
a Company office existing as of the date of this Agreement, unless the Executive would be based closer to his primary residence
and except for required travel on the Company&rsquo;s business to an extent substantially consistent with the Executive&rsquo;s
present business travel obligations, or (5) a material breach of this Agreement by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>


<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">The foregoing shall be
treated as Constructive Termination events hereunder following the expiration of 30 days from the date the Executive has notified
Company (within 90 days) of the occurrence of such event and the Executive&rsquo;s intention to treat such event as a constructive
termination and terminate the Executive&rsquo;s employment on the basis thereof, provided that Company has not cured the constructive
termination event before the expiration of such 30-day period. The Executive&rsquo;s termination will be effective upon the expiration
of the 30-day period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Disability.</U>
The Executive shall be treated as having suffered a &ldquo;Disability&rdquo; if the Executive is prevented from performing his
duties hereunder by reason of illness or injury for a period of either (A) six or more consecutive months from the First Date of
Disability (as defined below) or (B) eight months in the aggregate during any 12-month period. The date as of which the Executive
is first absent from employment as a result of such illness or injury shall be referred to herein as the &ldquo;First Date of Disability&rdquo;.
Notwithstanding the foregoing, if and only to the extent that Executive&rsquo;s disability is a trigger for the payment of deferred
compensation, as defined in Section 409A of the Code, &ldquo;disability&rdquo; shall have the meaning set forth in Section 409A(a)(2)(C)
of the Code.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(iv)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Change
in Control</U>. A &ldquo;Change in Control&rdquo; shall be deemed to have taken place if:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(A) there shall be consummated
any consolidation or merger of the Company in which Company is not the continuing or surviving corporation or pursuant to any transaction
in which shares of the Company&rsquo;s capital stock are converted into cash, securities or other property, or any sale, lease,
exchange or other transfer in one transaction or a series of transactions contemplated or arranged by any party as a single plan
of all or substantially all of the assets of the Company, or the approval of a plan of complete liquidation or dissolution of the
Company adopted by the stockholders of the Company; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(B) any person (as such
term is used in Sections 13(d) and 14(d)(2) of the Securities Exchange Act of 1934, as amended (the &ldquo;Exchange Act&rdquo;))
shall after the date hereof become the beneficial owner (as defined in Rules 13d-3 and 13d-5 under the Exchange Act), directly
or indirectly, of securities of the Company representing 35% or more of the voting power of all then outstanding securities of
the Company having the right under ordinary circumstances to vote in an election of the Board (including, without limitation, any
securities of the Company that any such person has the right to acquire pursuant to any agreement, or upon exercise of conversion
rights, warrants or options, or otherwise, shall be deemed beneficially owned by such person); or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(C) individuals who
at the date hereof constitute the entire Board and any new directors whose election by the Board, or whose nomination for election
by the Company&rsquo;s stockholders, shall have been approved by a vote of at least a majority of the directors then in office
who either were directors at the date hereof or whose election or nomination for election shall have been so approved (the &ldquo;Continuing
Directors&rdquo;) shall cease for any reason to constitute a majority of the members of the Board; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><U>provided
further</U> that in each of the foregoing cases, the Change of Control also meets all of the requirements of a &ldquo;change in
the ownership of a corporation&rdquo; within the meaning of Treasury Regulation &sect;1.409A-3(i)(5)(v), a &ldquo;change in the
effective control of a corporation&rdquo; within the meaning of Treasury Regulation &sect;1.409A-3(i)(5)(vi) or a &ldquo;a change
in the ownership of a substantial portion of the corporation&rsquo;s assets&rdquo; within in the meaning of Treasury Regulation
&sect;1.409A-3(i)(5)(vii).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Termination
Without Cause</U>. In the event of termination of the Executive&rsquo;s employment hereunder by Company &ldquo;Without Cause&rdquo;
(other than for a Termination for a Change of Control hereinafter separately provided for) the Executive shall be entitled to the
following severance pay and benefits:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Severance
Pay </I>- severance payments in the form of continuation of the Executive&rsquo;s base salary as in effect immediately prior to
such termination for a period of 12 months commencing on the sixtieth (60<SUP>th</SUP>) day following the effective date of such
termination;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Benefits
Continuation</I> - continued coverage under the Company&rsquo;s medical care and life insurance benefit plans in which the Executive
is participating at the time of termination, or equivalent coverage thereof, on the same terms as applicable to other executive
employees of the Company from time to time, over the same period with respect to which the Executive&rsquo;s base salary is continued
as provided in Section 9(b)(i) hereof; provided, however, that the Company&rsquo;s obligation to provide such coverages shall be
terminated if the Executive obtains substitute coverage from another employer of the Executive at any time during the continuation
period; the Executive shall be obligated to notify Company of any such substitute coverage and the date of commencement thereof
promptly upon obtaining any such coverage. The Executive shall be entitled, at the expiration of the period of benefits continuation
under this Section 9(b)(ii), to elect continued medical coverage upon timely election of COBRA continuation coverage, in accordance
with Section 4980B of the Internal Revenue Code of 1986, as amended (or any successor provision thereto) with the Company premiums
paid at the same percentage as prior to the Executive&rsquo;s termination; provided that, if COBRA continuation coverage is otherwise
earlier terminated under applicable law, then, in lieu of coverage, the Company will pay its share of the monthly Company premium
in effect prior to the termination of COBRA continuation coverage directly to the Executive each month for the remainder of the
relevant period. Any amounts paid by the Company on Executive&rsquo;s behalf under this Section 9(b)(ii) to continue the Executive&rsquo;s
medical care and life insurance benefits shall be recorded as additional income pursuant to Section 6041 of the Code and shall
not be entitled to any tax qualified treatment; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Stock
Options</I> - all options to purchase shares of the Company&rsquo;s common stock held by the Executive and which are vested immediately
prior to termination of employment shall become exercisable for a period of six months following the effective date of termination
of employment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Termination
following Change in Control</U>. In the event of termination of the Executive&rsquo;s employment within six months following a
Change of Control the Executive shall be entitled to the following severance pay and benefits:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Severance
Pay </I>-Severance payments in the form of continuation as the Executive&rsquo;s base salary as in effect immediately prior to
such termination for a period of 24 months commencing on the sixtieth (60<SUP>th</SUP>) day following the effective date of termination;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Benefits
Continuation</I> - continued coverage under the Company&rsquo;s medical care and life insurance benefit plans in which the Executive
is participating at the time of termination, or equivalent coverage thereof, on the same terms as applicable to other executive
employees of the Company from time to time, over the same period with respect to which the Executive&rsquo;s base salary is continued
as provided in Section 9(c)(i) hereof; provided, however, that the Company&rsquo;s obligation to provide such coverages shall be
terminated if the Executive obtains substitute coverage from another employer of the Executive at any time during the continuation
period; the Executive shall be obligated to notify Company of any such substitute coverage and the date of commencement thereof
promptly upon obtaining any such coverage. The Executive shall be entitled, at the expiration of the period of benefits continuation
under this Section 9(c)(ii), to elect continued medical coverage upon timely election of COBRA continuation coverage, in accordance
with Section 4980B of the Internal Revenue Code of 1986, as amended (or any successor provision thereto) with the Company premiums
paid at the same percentage as prior to the Executive&rsquo;s termination; provided that, if COBRA continuation coverage is otherwise
earlier terminated under applicable law, then, in lieu of coverage, the Company will pay its share of the monthly Company premium
in effect prior to the termination of COBRA continuation coverage directly to the Executive each month for the remainder of the
relevant period. Any amounts paid by the Company on Executive&rsquo;s behalf under this Section 9(c)(ii) to continue the Executive&rsquo;s
medical care and life insurance benefits shall be recorded as additional income pursuant to Section 6041 of the Code and shall
not be entitled to any tax qualified treatment; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Stock
Options</I> - all options to purchase shares of the Company&rsquo;s common stock held by the Executive shall be vested and be exercisable
for a period of 18 months following the effective date of termination; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(iv)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Return
to London</I> - the Company will reimburse Executive for out of pocket expenses reasonably incurred by the Executive, subject to
an aggregate cap of $15,000, in connection with the relocation of Executive&rsquo;s family and household goods from the New York-New
Jersey metropolitan area to London, provided, however, that (i) the Executive actually relocates his family and household goods
within one year following the date the termination of his employment becomes effective; and (ii) all such expenses are reimbursed
on or before the last day of the second taxable year following the year in which the Executive&rsquo;s employment terminated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>


<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(v)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>280G
Excise Tax</I> - it is the intention of Executive and the Company that no payments made or benefits provided by the Company to
or for the benefit of Executive under this Agreement or any other agreement or plan pursuant to which Executive is entitled to
receive payments or benefits shall be subject to the excise tax imposed on the Executive by Section 4999 of the Code (the &ldquo;280G
Excise Tax&rdquo;), relating to golden parachute payments. The Company agrees that in the event any payments to Executive pursuant
to this Agreement would result in a payment to Executive that would trigger any 280G Excise Tax, if appropriate and permissible,
the Company shall first submit to its stockholders for approval the transaction that may result in the imposition of the 280G Excise
Tax upon Executive in accordance with the regulations of the Internal Revenue Code governing shareholder approval of transactions
giving rise to 280G Excise Tax liability.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Termination
Upon Disability or Death</U>. In the event of termination of the Executive&rsquo;s employment hereunder on account of the Executive&rsquo;s
&ldquo;Disability&rdquo; or death, the Executive or the Executive&rsquo;s heirs, estate or personal representatives under law,
as applicable, shall be entitled to the following severance pay and benefits:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Severance
Pay</I> - severance payments in the form of continuation of the Executive&rsquo;s base salary as in effect immediately prior to
such termination for a period of 12 months commencing on the sixtieth (60<SUP>th</SUP>) day following the effective date of the
termination, reduced by any amounts paid to the Executive in the time period following the First Date of Disability and until the
date of termination, and any payments received from any short-term or long-term disability plan of the Company;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Benefits
Continuation</I> - the same benefits as provided in Section 9(c)(ii) above, to be provided during the Employment Period while the
Executive is suffering from Disability and for a period of 12 months following the effective date of termination of employment
by reason of Disability; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Stock
Options</I> - all options to purchase shares of the Company&rsquo;s common stock held by the Executive which are exercisable immediately
prior to termination of employment shall remain exercisable for a period of 12 months following the effective date of termination
of employment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Other
Terminations</U>. In the event of termination of the Executive&rsquo;s employment hereunder for any reason other than those specified
in subsections (b) through (d) of this Section 9, the Executive shall not be entitled to any severance pay, benefits continuation
or stock option rights contemplated by the foregoing provisions of this Section 9, except as otherwise provided in the applicable
benefit plans of the Company that cover the Executive.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Accrued
Rights</U>. Notwithstanding the foregoing provisions of this Section 9, in the event of termination of the Executive&rsquo;s employment
hereunder for any reason, the Executive shall be entitled to payment of any unpaid portion of his base salary, computed on a pro-rata
basis through the effective date of termination, and payment of any accrued but unpaid rights in accordance with the terms of any
incentive bonus or employee benefit plan or program of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(g)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Conditions
to Severance Benefits</U>. (i) As conditions of the Executive&rsquo;s entitlement and continued entitlement to the severance payments
and benefits provided by this Section 9, the Executive is required to (i) honor in accordance with their terms the provisions of
Sections 10, 11 and 12 hereof and (ii) execute and honor the terms of a waiver and release of claims against the Company substantially
in the form attached hereto as Exhibit A (and as may be modified consistent with the purposes of such waiver and release to reflect
changes in law following the date hereof), which must be effective and irrevocable prior to the sixtieth (60<SUP>th</SUP>) day
following the effective date of the termination of the Executive&rsquo;s employment. The parties hereto agree that the Executive
is under no affirmative obligation to seek to mitigate or offset the severance payments and benefits provided by this Section 9.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(ii) &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;For
purposes only of this Section, the Executive shall be treated as having failed to honor the provisions of Sections 10, 11 or 12
hereof only upon the passing of a resolution by a majority of the Board making such a determination following notice of the alleged
failure by Company to the Executive, an opportunity for the Executive to cure the alleged failure for a period of 30 days from
the date of such notice and the Executive&rsquo;s opportunity to be heard on the issue by the Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(iii) &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Stock
Options</U>. Notwithstanding any other provisions of this Agreement to the contrary, in the event that the Executive continues
to serve as a member of the Board following his termination of employment from the Company, his rights with respect to vesting
and exercisability of his then outstanding options shall continue under the same terms and conditions as if the Executive had not
terminated employment until such time as the Executive is no longer providing services to the Company as a non-executive member
of the Board. In addition, any option which is deemed to be an Incentive Stock Option pursuant to Section 422 of the Code, shall
become a Nonqualified Stock Option on the date that is three months after termination of Executive&rsquo;s employment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">10.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><B><U>Confidentiality</U></B>.
The Executive agrees that he will not at any time during the term hereof or thereafter for any reason, in any fashion, form or
manner, either directly or indirectly, divulge, disclose or communicate to any person, firm, corporation or other business entity,
in any manner whatsoever, any confidential information or trade secrets concerning the business of the Company (including the business
of any unit thereof), including, without limiting the generality of the foregoing, the names of any of its customers, the prices
at which it obtains or has obtained any products or services, the techniques, methods or systems of its operation or management,
any customer proposals or other business opportunities, any information regarding its financial matters, or any other material
information concerning the business of the Company, its manner of operation, its plans or other material data. The provisions of
this paragraph shall not apply to (i) information disclosed in the performance of the Executive&rsquo;s duties to the Company based
on his good faith belief that such a disclosure is in the best interests of the Company; (ii) information that is public knowledge;
(iii) information disseminated by the Company to others in the ordinary course of the Company&rsquo;s business, in order to further
such business, provided the recipient of such information agrees to be subject to a confidentiality obligation at least comparable
to that herein; (iv) information or knowledge lawfully received by the Executive from a third party who, based upon due inquiry
by the Executive, is not bound by a confidential relationship to the Company; or (v) information disclosed under a requirement
of law or as directed by applicable legal authority having jurisdiction over the Executive.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">11.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><B><U>Inventions</U></B>.
(i) To the extent that any of the Company&rsquo;s current or future products or services relate to, embody or incorporate concepts,
technology or products of any kind relevant to the Company or its subsidiaries or affiliates that the Executive directly or indirectly
conceived or developed prior to the date hereof during the period of his employment by Company (&ldquo;Prior Technology&rdquo;),
the Executive assigns in perpetuity to Company any and all of his rights, title and interests, if any, to utilize, without any
cost to the Company, such Prior Technology, and the Executive agrees to assist Company in taking all action that may be reasonably
required, at the Company&rsquo;s expense, to secure for the Company the benefits of the Executive&rsquo;s ownership or rights,
if any, to use all such Prior Technology.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(ii) The Executive
is hereby retained in a capacity such that the Executive&rsquo;s responsibilities include the making of technical, managerial and
promotional contributions of value to the Company. The Executive hereby assigns to Company all rights, title and interest in such
contributions and inventions made or conceived by the Executive alone or jointly with others which relate to the business of the
Company. This assignment shall include (a) the right to file and prosecute patent applications on such inventions in any and all
countries, (b) the patent applications filed and patents issuing thereon, and (c) the right to obtain copyright, trademark or trade
name protection for any such work product. The Executive shall promptly and fully disclose all such contributions and inventions
to the Company and assist the Company in obtaining and protecting the rights therein (including patents thereon), in any and all
countries; provided, however, that said contributions and inventions will be the property of the Company, whether or not patented
or registered for copyright, trademark or trade name protection, as the case may be. Inventions conceived by the Executive which
are not related to the business of the Company (as determined in good faith by the Board), will remain the property of the Executive.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">12.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><B><U>Non-Competition</U></B>.
(i) the Executive agrees that he shall not during the Employment Period and for a period of one year after the termination or end
thereof for any reason, without the approval of the Board which, after the end of the Employment Period, shall not unreasonably
be withheld or delayed, directly or indirectly, alone or as partner, joint venturer, officer, director, employee, consultant, agent,
independent contractor or controlling stockholder (other than as provided below) of any Company or business, engage in any &ldquo;Competitive
Business&rdquo; within the United States and within the United Kingdom. For purposes of the foregoing, the term &ldquo;Competitive
Business&rdquo; shall mean any business involved in the research, development, or sale of anticancer targeted therapeutics that
are nucleoside analogues, CDK inhibitors or Aurora/VEGFR2 inhibitors and/or medicines for the treatment of radiation dermatitis
or xerostomia or any other business in which the Company has been engaged up to and until the relevant time (as determined by the
Board of Directors); provided that, this provision shall in no way prevent the Executive, after the end of the Employment Period,
from being employed as a consultant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(ii) Notwithstanding
the provisions of clause (i) above or any other provision of this Agreement to the contrary, the Executive shall not be prohibited
during the period applicable under clause (i) above from acting as a passive investor where (a) in the case of a Competitive Business
being a public corporation, the Executive owns not more than five percent (5%) of the issued and outstanding capital stock or such
higher percentage or amount as may be approved by the Board upon notice from the Executive prior to obtaining such interest; provided,
however, that the Executive shall not be treated as having violated the provisions of this Section 12 if in good faith he is unaware
that an entity in which he has an investment interest would be treated as a Competitive Business and, upon becoming aware of such
involvement, the Executive makes reasonable efforts to divest himself of his interest in such business; (b) in the case of any
employer or entity other than a Competitive Business that is engaged in, or whose affiliates are engaged in, the development or
marketing of products or technologies that are directly or indirectly competitive with any product or technology that is developed
or marketed or proposed to be developed or marketed by Company during the Employment Period, the Executive owns not more than five
percent (5%) of the issued and outstanding capital stock; or (c) receiving stock, options or warrants from any entity with which
the Executive can have a relationship pursuant to clause (i) above as part of the Executive&rsquo;s compensation for services rendered
or to be rendered.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">13.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><B><U>Breach
of Restrictive Covenants.</U></B> The parties agree that a breach or violation of Sections 10, 11 or 12 hereof will result in immediate
and irreparable injury and harm to the innocent party, who shall have, in addition to any and all remedies of law and other consequences
under this Agreement, the right to an injunction, specific performance or other equitable relief to prevent the violation of the
obligations hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="text-transform: uppercase">14.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><B><U>Non-Disparagement</U></B>.
The Executive agrees that he will not, whether during his provision of services to the Company or thereafter, directly or indirectly,
make, cause to be made, or ratify any statement, public or private, oral or written, to any person that disparages, either professionally
or personally, the Company or any of its affiliates, past and present, and each of them, as well as its and their trustees, directors,
officers, agents, attorneys, insurers, employees, stockholders, representatives, assigns, and successors, past and present, and
each of them<FONT STYLE="font-size: 10pt">.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">15.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><B><U>Notices</U></B>.
Any notice required to be given pursuant to the provisions of this Agreement shall be in writing and, if mailed, sent by registered
mail, postage prepaid, to the party named at the address set forth below, or at such other address as each party may hereafter
designate in writing to the other party:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 10%"><FONT STYLE="font-size: 10pt">Company:</FONT></TD>
    <TD STYLE="width: 40%"><FONT STYLE="font-size: 10pt">200 Connell Drive #1500</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Berkeley Heights, NJ 07922</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Attention: Chairman of the Board</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">with a copy to (which copy will not constitute notice):</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Mintz Levin Cohn Ferris Glovsky &amp; Popeo, P.C.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">666 Third Avenue</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">New York, New York 10017</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Attention:&nbsp;&nbsp;Joel Papernik, Esq.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 10%"><FONT STYLE="font-size: 10pt">Executive: </FONT></TD>
    <TD STYLE="width: 40%"><FONT STYLE="font-size: 10pt">c/o Cyclacel Pharmaceuticals, Inc.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">200 Connell Drive #1500</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Berkeley Heights, NJ 07922</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Any such notices shall be deemed to have
been delivered when served personally in the manner specified above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">16.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><B><U>Dispute
Resolution</U></B>. The parties shall waive trial by jury in any dispute between them.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">17.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><B><U>Entire
Agreement</U></B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Change,
Modification, Waiver</U>. No change or modification of this Agreement shall be valid unless it is in writing and signed by each
of the parties hereto. No waiver of any provision of this Agreement shall be valid unless it is in writing and signed by the party
against whom the waiver is sought to be enforced. The failure of a party to insist upon strict performance of any provision of
this Agreement in any one or more instances shall not be construed as a waiver or relinquishment of the right to insist upon strict
compliance with such provision in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Integration
of All Agreements</U>. This Agreement constitutes the entire Agreement between the parties and is intended to be an integration
of all agreements between the parties with respect to the Executive&rsquo;s service with Company. Except as provided in Section
8 hereof concerning the Indemnification Agreement, any and all prior agreements between the Executive and the Company with respect
to the Executive&rsquo;s service with the Company are hereby revoked.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Severability
of Provisions</U>. If for any reason any provision of this Agreement should be declared void or invalid, such declaration shall
not affect the validity of the rest of this Agreement, which shall remain in force as if executed with the void or invalid provision
eliminated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">18.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><B><U>Binding
Effect</U></B>. This Agreement shall be binding upon all parties hereto and their heirs, successors and assigns. This Agreement
shall be assignable by Company to any entity acquiring all or substantially all of the assets of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">19.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><B><U>Governing
Law</U></B>. This Agreement shall be governed by and construed in accordance with the laws of the State of New Jersey.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">20.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><B><U>Miscellaneous.</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Form</U>.
As employed in this Agreement, the singular form shall include, if appropriate, the plural.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Headings</U>.
The headings employed in this Agreement are solely for the convenience and reference of the parties and are not intended to be
descriptive of the entire contents of any paragraph and shall not limit or otherwise affect any of terms, provisions, or construction
thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">21.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><B><U>Compliance
with Section 409A of the Code</U></B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To
the extent any of the benefits payable under Section 9(b), (c) or (d) of this Agreement constitute non-qualified deferred compensation
subject to Section 409A of the Code, the following provisions shall apply:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in; text-align: justify">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any
termination of employment triggering payment of such benefits must constitute a &ldquo;separation from service&rdquo; under Section
409A of the Code before distribution of such benefits can commence. For purposes of clarification, this paragraph shall not cause
any forfeiture of benefits on the part of the Executive, but shall only act as a delay until such time as a &ldquo;separation from
service&rdquo; occurs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in; text-align: justify">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
the Executive is a &ldquo;specified employee&rdquo; (as that term is used in Section 409A of the Code and regulations and other
guidance issued thereunder) on the date his separation from service becomes effective, any benefits payable under Section 9 that
constitute non-qualified deferred compensation subject to Section 409A of the Code shall be delayed until the earlier of (A) the
business day following the six-month anniversary of the date his separation from service becomes effective, and (B) the date of
the Employee&rsquo;s death, but only to the extent necessary to avoid the imposition of accelerated or increased income taxes,
excise taxes or other penalties under Section 409A of the Code. On the earlier of (A) the business day following the six-month
anniversary of the date his separation from service becomes effective, and (B) the Executive&rsquo;s death, the Company shall pay
the Executive in a lump sum the aggregate value of the non-qualified deferred compensation that the Company otherwise would have
paid the Executive prior to that date under Section 9 of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in; text-align: justify">(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;It
is intended that each installment of the payments and benefits provided under Section 9 this Agreement shall be treated as a separate
&ldquo;payment&rdquo; for purposes of Section 409A of the Code. In particular, if the installment severance payments set forth
in Sections 9(b)(i), 9(c)(i) and 9(d)(i) of this Agreement otherwise qualify under Treas. Reg. &sect;1.409A-1(b)(9)(iii) as an
involuntary separation plan, the installment severance payments shall be divided into two portions. That number of installments
commencing on the first payment date set forth in Sections 9(b)(i), 9(c)(i) and 9(d)(i) of this Agreement that are in the aggregate
less than two times the applicable compensation limit under Section 401(a)(17) of the Code for the year in which the termination
of the Executive&rsquo;s employment occurs (provided the termination of the Executive&rsquo;s employment is also a &ldquo;separation
from service&rdquo;) shall be payable in accordance with Treas. Reg. &sect;1.409A-1(b)(9)(iii) as an involuntary separation plan.
The remainder of the installments shall be paid in accordance with Sections 21(a)(i) and (ii) above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in; text-align: justify">(iv)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Neither
the Company nor Executive shall have the right to accelerate or defer the delivery of any such payments or benefits except to the
extent specifically permitted or required by Section 409A of the Code.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Notwithstanding
any other provision of this Agreement to the contrary, if any term in the Agreement is ambiguous, such term or terms shall be interpreted
in a manner that avoids the inclusion of compensation in income under Section 409A(a)(1) of the Code. For purposes of clarification,
this Section 20 shall be a rule of construction and interpretation and nothing in this Section 20 shall cause a forfeiture of benefits
on the part of the Executive.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>[signature page follows]</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>IN WITNESS WHEREOF</B>, this Agreement
is executed as of the date first above written.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in; text-align: justify"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 50%"><FONT STYLE="font-size: 10pt; text-transform: uppercase"><B>Cyclacel Pharmaceuticals, Inc.</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="width: 6%"><FONT STYLE="font-size: 10pt">Name</FONT></TD>
    <TD STYLE="width: 40%; border-bottom: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Title</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 50%"><FONT STYLE="font-size: 10pt; text-transform: uppercase"><B>Spiro Rombotis</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.5in; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">EXHIBIT A</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Your
Release of Claims.</U></B> You hereby agree and acknowledge that by signing this Agreement, and for other good and valuable consideration,
you are waiving your right to assert any and all forms of legal claims against the Company<FONT STYLE="font-family: Times New Roman, Times, Serif"><SUP>1</SUP></FONT><SUP>/</SUP>
of any kind whatsoever, whether known or unknown, arising from the beginning of time through the date you execute this Agreement
(the &ldquo;Execution Date&rdquo;). Except as set forth below, your waiver and release herein is intended to bar any form of legal
claim, complaint or any other form of action (jointly referred to as &ldquo;Claims&rdquo;) against the Company seeking any form
of relief including, without limitation, equitable relief (whether declaratory, injunctive or otherwise), the recovery of any damages,
or any other form of monetary recovery whatsoever (including, without limitation, back pay, front pay, compensatory damages, emotional
distress damages, punitive damages, attorneys&rsquo; fees and any other costs) against the Company, for any alleged action, inaction
or circumstance existing or arising through the Execution Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Without limiting the
foregoing general waiver and release, you specifically waive and release the Company from any Claim arising from or related to
your prior employment relationship with the Company or the termination thereof, including, without limitation:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">**</TD><TD STYLE="text-align: justify">Claims under any state or federal discrimination, fair employment practices or other employment
related statute, regulation or executive order (as they may have been amended through the Execution Date) prohibiting discrimination
or harassment based upon any protected status including, without limitation, race, national origin, age, gender, marital status,
disability, veteran status or sexual orientation. Without limitation, specifically included in this paragraph are any Claims arising
under the Age Discrimination in Employment Act, Title VII of the Civil Rights Act of 1964, the Civil Rights Act of 1991, the Americans
With Disabilities Act and any similar Federal and state statute.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">**</TD><TD STYLE="text-align: justify">Claims under any other state or federal employment related statute, regulation or executive order
(as they may have been amended through the Execution Date) relating to wages, hours or any other terms and conditions of employment.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">**</TD><TD STYLE="text-align: justify">Claims under any state or federal common law theory including, without limitation, wrongful discharge,
breach of express or implied contract, promissory estoppel, unjust enrichment, breach of a covenant of good faith and fair dealing,
violation of public policy, defamation, interference with contractual relations, intentional or negligent infliction of emotional
distress, invasion of privacy, misrepresentation, deceit, fraud or negligence.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">**</TD><TD STYLE="text-align: justify">Any other Claim arising under state or federal law.</TD></TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 25%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; text-align: justify"><SUP>1/&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</SUP> For purposes of this Agreement, the Company includes the Company and any of its divisions, affiliates (which means all persons and entities directly or indirectly controlling, controlled by or under common control with the Company), subsidiaries and all other related entities, and its and their directors, officers, employees, trustees, agents, successors and assigns.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Notwithstanding the
foregoing, nothing contained in this Release constitutes a waiver of any Claims you may have against the Company arising from or
related to the Indemnification Agreement and By-laws provisions referenced in Section 8 of the Employment Agreement, dated January
1, 2014, entered into between you and the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">You acknowledge and
agree that, but for providing this waiver and release, you would not be receiving the economic benefits being provided to you under
the terms of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>It is the Company&rsquo;s
desire and intent to make certain that you fully understand the provisions and effects of this Agreement. To that end, you have
been encouraged and given the opportunity to consult with legal counsel for the purpose of reviewing the terms of this Agreement.
Also, because you are over the age of 40 and consistent with the provisions of the Age Discrimination in Employment Act (&ldquo;ADEA&rdquo;),
which prohibits discrimination on the basis of age, the Company is providing you with twenty-one (21) days in which to consider
and accept the terms of this Agreement by signing below and returning it to me at: [name], [address].</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>You may rescind
your assent to this Agreement if, within seven (7) days after you sign this Agreement, you deliver by hand or send by mail (certified,
return receipt and postmarked within such 7 day period) a notice of rescission to me at the Company. The eighth day following your
signing of this Agreement is the Effective Date.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Also, consistent with
the provisions of Federal and state discrimination laws, nothing in this release shall be deemed to prohibit you from challenging
the validity of this release under such discrimination laws (the &ldquo; Discrimination Laws&rdquo;) or from filing a charge or
complaint of age or other employment related discrimination with the Equal Employment Opportunity Commission (&ldquo;EEOC&rdquo;)
or state equivalent, or from participating in any investigation or proceeding conducted by the EEOC or state equivalent. Further,
nothing in this release or Agreement shall be deemed to limit the Company&rsquo;s right to seek immediate dismissal of such charge
or complaint on the basis that your signing of this Agreement constitutes a full release of any individual rights under the Discrimination
Laws, or to seek restitution to the extent permitted by law of the economic benefits provided to you under this Agreement in the
event that you successfully challenge the validity of this release and prevail in any claim under the Discrimination Laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.5in; text-align: justify; text-indent: -0.5in"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 4%"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="width: 46%; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-left: 0.25in"><FONT STYLE="font-size: 10pt">Spiro Rombotis</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 11%"><FONT STYLE="font-size: 10pt">Date signed:</FONT></TD>
    <TD STYLE="width: 39%; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 16; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>3
<FILENAME>tv481140_ex10-2.htm
<DESCRIPTION>EXHIBIT 10.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: right"><FONT STYLE="text-transform: none">Exhibit
10.2</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B><I>EXECUTION COPY</I></B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">EMPLOYMENT
AGREEMENT</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>THIS EMPLOYMENT
AGREEMENT</B> (the &ldquo;Agreement&rdquo;) is made as of January 1, 2017 by and between Cyclacel Pharmaceuticals, Inc. (the &ldquo;Company&rdquo;),
a Delaware corporation, and Paul McBarron (the &ldquo;Executive&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>WHEREAS, </B>Company
and Executive were parties to an Employment Agreement dated January 1, 2014, which expires by its terms on January 1, 2017;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>WHEREAS</B>, Company
and Executive mutually extended the term of the Employment Agreement dated January 1, 2014 through December 31, 2017;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>WHEREAS,</B> Company
desires to continue to retain the Executive&rsquo;s services as its <FONT STYLE="background-color: white">Executive Vice President,
Finance, Chief Financial Officer, Chief Operating Officer and Secretary; and </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>WHEREAS,</B> Company
and the Executive are desirous of agreeing the terms and conditions of the Executive&rsquo;s employment with the Company as set
forth herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>NOW, THEREFORE,</B>
in consideration of the foregoing and the mutual covenants and conditions herein contained, the parties hereby agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Employment</U>.</B>
Company hereby employs the Executive and the Executive accepts such employment according to the terms and conditions set forth
in this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Term</U>.</B>
Except for earlier termination as hereinafter provided for, the term of the Executive&rsquo;s employment hereunder shall be for
a period commencing on January 1, 2017 (the &ldquo;Commencement Date&rdquo;) and continuing through January 1, 2019, the second
anniversary of the Commencement Date. Notwithstanding the foregoing, the Executive&rsquo;s employment by the Company hereunder
may be earlier terminated, subject to <U>Section 9</U> hereof, upon the occurrence of any one of the following events: (i) the
Company&rsquo;s decision to terminate the Executive, (ii) the Executive&rsquo;s decision to voluntarily resign or retire at any
time or (iii) the parties&rsquo; mutual agreement in writing to terminate the Executive&rsquo;s employment hereunder at any time.
The period of time between the Commencement Date and termination of the Executive&rsquo;s employment hereunder shall be referred
to herein as the &ldquo;Employment Period&rdquo;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Position
and Services</U>.</B> (i) The Executive will hold the position of <FONT STYLE="background-color: white">Executive Vice President,
Finance, Chief Financial Officer, Chief Operating Officer and Secretary</FONT>. The Executive will report directly to the Company&rsquo;s
President and Chief Executive Officer and shall have such duties, responsibilities and authority with respect to such positions
as are set forth in the Bylaws of the Company, which duties and responsibilities shall in all events include, but not be limited
to, management responsibility for the operations, finance and administration of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>


<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Executive will be expected to be in the full-time employment of the Company, to devote substantially all of his business time,
attention and efforts to the performance of his duties hereunder. Notwithstanding the foregoing, the Executive may make and manage
personal business investments of his choice and serve in any capacity with any civic, educational or charitable organization, or
any trade association, without seeking or obtaining approval from the Board and/or the President and Chief Executive Officer, provided
such activities and service do not materially interfere or conflict with the performance of his duties hereunder or violate the
non-competition provisions of <U>Section 12</U> hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Executive expressly agrees that during the Employment Period he will not be interested, directly or indirectly, in any form, fashion
or manner, as a partner, officer, director, advisor, employee, consultant, controlling stockholder or in any other form or capacity,
in any other business or company, except that he would not be prohibited by <U>Section 12</U> hereof to serve as (a) member of
one other Board of Directors of a commercial organization, or (b) a member of one or more Boards of Directors or Trustees of a
charitable organization, as may, upon advance notice from the Executive be approved by the Board in its discretion after consideration
of possible conflicts, reputation(al) effects, time requirements and other interests of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Executive is currently serving as a
Class 3 director on the Company&rsquo;s Board for a term ending at the 2018 annual meeting. At the 2018 annual meeting of the Company&rsquo;s
shareholders, the Board will use its best efforts to cause the nomination of the Executive to serve as a Class 3 director of the
Board for a term ending at the 2021 annual meeting. The Board will use its best efforts to cause the nomination of the Executive
thereafter for reelection as a Class 3 director to the Board for successive terms, at every time at which Class 3 directors are
nominated to the stockholders for election, as long as the Executive serves as Executive <FONT STYLE="background-color: white">Vice
President, Finance, Chief Financial Officer, Chief Operating Officer and Secretary </FONT>unless the Executive declines such nomination
in writing to the Board. As with all members of the Board, the Executive&rsquo;s continuation as a director requires election as
a director by the stockholders whenever directors are to be elected by the stockholders. If the Executive ceases to serve as Executive
Vice President, Finance, Chief Financial Officer, Chief Operating Officer and Secretary for any reason, and the Board thereafter
requests that the Executive resigns as a director of the Board, the Executive shall immediately resign as a director of the Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Base
Salary</U>.</B> Company shall pay to the Executive an initial base salary at an annual rate of &pound;208,859, subject to applicable
income and employment tax withholdings and all other required and authorized payroll deductions and withholdings. The Executive&rsquo;s
salary shall be payable at the same time and basis as the Company pays its payroll in general. Increases in the Executive&rsquo;s
annual base salary during the Employment Period may be effected from time to time based upon the review and approval of the Compensation
Committee of the Board (the &ldquo;Compensation Committee&rdquo;). During the Employment Period, the Executive&rsquo;s base salary
rate shall not be reduced below the initial base salary rate provided hereunder, nor below any increased base salary rate that
may be effected as provided hereunder, except if the Board, in response to exceptionally adverse business circumstances makes a
general temporary reduction in the compensation of the executives of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 2; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Annual
Incentive Bonus</U>.</B> In addition to the Executive&rsquo;s base salary as provided above, the Executive will be eligible for
an annual cash incentive bonus for each calendar year of the Employment Period. The bonus for which the Executive is eligible for
each such year will be based on a target percentage of the then current base salary, which target percentage shall be at least
50% of Executive&rsquo;s then current base salary. The determination of the amount of the annual cash incentive bonus will be based
upon the satisfaction of performance criteria established by the Compensation Committee in its discretion and upon consultation
with the Executive at the beginning of each year and subject to the approval of the Board. Depending on the Executives performance
against the performance criteria, the actual annual cash incentive bonus may be more, equal to or less than the target. Such performance
criteria will include corporate performance goals consistent with the Company&rsquo;s business plan for the year, as well as individual
objectives for the Executive&rsquo;s performance that may be separate from, but are consistent with, the Company&rsquo;s business
plan. The final determinations as to the actual corporate and individual performance against the pre-established goals and objectives,
and the amount of the bonus payout in relationship to such performance, will be made by the Compensation Committee in its sole
discretion. To the extent the Company awards the Executive a cash bonus, the bonus, if payable, shall be calculated and paid no
later than two and a half months following the later of the close of the calendar or Company fiscal year to which such bonus relates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Executive
Benefits</U>.</B> The Executive shall be entitled to receive employment benefits in accordance with the Company&rsquo;s benefit
policies in effect for senior executives employed in the United Kingdom from time to time, including, without limitation, personal
pension plan, private medical, dental and life insurance, accidental death, travel accident, long term disability insurance, profit
sharing and long term incentive plans, 25 working days of paid vacation and 10 days of UK public holidays annually, as established
from time to time by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Expenses</U>.</B>
The Company shall reimburse the Executive for all reasonable and necessary expenses incurred by him in connection with the performance
of his services for the Company upon submission of expense reports and documentation in accordance with the Company&rsquo;s policies.
The Company may request additional documentation or a further explanation to substantiate any expense submitted for reimbursement,
and retains the discretion to approve or deny a request for reimbursement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Indemnification</U>.</B>
The Company shall indemnify the Executive in accordance with the Company&rsquo;s By-laws. The Company agrees that it will make
all commercially reasonable efforts to keep in full force and effect, for the duration of all applicable statute of limitations
periods, directors and officers liability insurance policies on terms at least as favorable to the Executive as those in effect
on the date hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Termination</U>.</B>
This Agreement does not grant the Executive any right or entitlement to be retained by the Company. In the event of termination
by the Company of the Executive&rsquo;s employment under the circumstances described below in this <U>Section 9</U>, the Executive
shall be entitled to the severance pay and benefits so specified.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>


<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Certain
Definitions</U>. For purposes of this <U>Section 9</U>, the following terms shall have the meanings given below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Termination
For Cause</U>. The employment of the Executive hereunder shall be deemed to have been terminated &ldquo;For Cause&rdquo; if the
Company shall have terminated the Executive as a result of any of the following: (A) any act committed by the Executive which shall
represent a breach in any material respect of any of the terms of this Agreement and which breach is not cured within thirty (30)
days of receipt by the Executive of written notice from the Company of such breach; (B) improper conduct, consisting of any willful
act or omission with the intent of obtaining, to the material detriment of the Company, any benefit to which the Executive would
not otherwise be entitled; (C) gross negligence, consisting of wanton and reckless acts or omissions in the performance of the
Executive&rsquo;s duties to the material detriment of the Company; (D) addiction to drugs or chronic alcoholism or (E) any conviction
of, or plea of nolo contendere to, a crime (other than a traffic violation) under the laws of the United States, the United Kingdom,
or any of their respective political subdivisions, provided that the Executive receives a copy of a resolution duly adopted by
a two thirds majority affirmative vote of the membership of the Board excluding the Executive, at a meeting of the Board called
and held for such purpose after the Executive has been given reasonable notice of such meeting and has been given an opportunity,
together with his counsel, to be heard by the Board, finding that in the good faith opinion of the Board the Executive was guilty
of the conduct set forth and specifying the particulars thereof in detail.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Termination
Without Cause</U>. The employment of the Executive hereunder shall be deemed to have been terminated &ldquo;Without Cause&rdquo;
upon (A) termination of employment by the Company for any reason other than the reasons specified in <U>Section 9(a)(i)</U> hereof
as termination &ldquo;For Cause&rdquo; or the reasons specified in <U>Section 9(a)(iii)</U> hereof as termination because of the
Executive&rsquo;s Death or Disability, (B) termination of employment by the Company by virtue of the expiry of the Employment Period
on 1 January 2019 (or any specific extension thereof), unless the Company has offered in writing to renew the Executive&rsquo;s
employment after the expiry of the Employment Period on terms no less favorable than those provided in this Agreement (in which
case if the Executive does not accept renewal of his employment, the termination of his employment by virtue of expiry of the Employment
Term will be deemed a resignation by the Executive), or (C) termination of employment by the Executive within thirty (30) days
following a &ldquo;Constructive Termination&rdquo; event. For purposes hereof, the following shall constitute Constructive Termination
events: (1) any removal of the Executive from the position of Executive <FONT STYLE="background-color: white">Vice President, Finance,
Chief Financial Officer and Chief Operating Officer</FONT>, (2) any material reduction of the Executive&rsquo;s duties, responsibilities
or authority, including any change in the Executive&rsquo;s positions as Executive <FONT STYLE="background-color: white">Vice President,
Finance, Chief Financial Officer and Chief Operating Officer </FONT>that results in such a reduction, (3) a material reduction
by the Company in the Executive&rsquo;s base salary in effect on the date hereof or as may be increased from time to time except
if the Board in response to exceptional adverse business circumstances makes a general temporary reduction in the compensation
of the executives of the Company, (4) the Company&rsquo;s requiring the Executive without the Executive&rsquo;s express written
consent to be based anywhere other than within 50 miles of the Executive&rsquo;s present office location in the United Kingdom,
except for required travel on the Company&rsquo;s business to an extent substantially consistent with the Executive&rsquo;s present
business travel obligations, or (5) a material breach of this Agreement by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The foregoing shall
be treated as Constructive Termination events hereunder following the expiration of 30 days from the date the Executive has notified
Company (within 90 days) of the occurrence of such event and the Executive&rsquo;s intention to treat such event as a constructive
termination and terminate the Executive&rsquo;s employment on the basis thereof, provided that Company has not cured the constructive
termination event before the expiration of such 30-day period. The Executive&rsquo;s termination will be effective upon the expiration
of the 30-day period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Disability</U>.
The Executive shall be treated as having suffered a &ldquo;Disability&rdquo; if the Executive is prevented from performing his
duties hereunder by reason of illness or injury for a period of either (A) six or more consecutive months from the First Date of
Disability (as defined below) or (B) eight months in the aggregate during any 12-month period. The date as of which the Executive
is first absent from employment as a result of such illness or injury shall be referred to herein as the &ldquo;First Date of Disability&rdquo;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(iv)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Change
in Control</U>. A &ldquo;Change in Control&rdquo; shall be deemed to have taken place if:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(A)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>there
shall be consummated any consolidation or merger of the Company in which Company is not the continuing or surviving corporation
or pursuant to any transaction in which shares of the Company&rsquo;s capital stock are converted into cash, securities or other
property, or any sale, lease, exchange or other transfer in one transaction or a series of transactions contemplated or arranged
by any party as a single plan of all or substantially all of the assets of the Company, or the approval of a plan of complete liquidation
or dissolution of the Company adopted by the stockholders of the Company; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(B)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>any
person (as such term is used in <U>Sections 13(d)</U> and 14(d)(2) of the Securities Exchange Act of 1934, as amended (the &ldquo;Exchange
Act&rdquo;)) shall after the date hereof become the beneficial owner (as defined in Rules 13d-3 and 13d-5 under the Exchange Act),
directly or indirectly, of securities of the Company representing 35% or more of the voting power of all then outstanding securities
of the Company having the right under ordinary circumstances to vote in an election of the Board (including, without limitation,
any securities of the Company that any such person has the right to acquire pursuant to any agreement, or upon exercise of conversion
rights, warrants or options, or otherwise, shall be deemed beneficially owned by such person); or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(C)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>individuals
who at the date hereof constitute the entire Board and any new directors whose election by the Board, or whose nomination for election
by the Company&rsquo;s stockholders, shall have been approved by a vote of at least a majority of the directors then in office
who either were directors at the date hereof or whose election or nomination for election shall have been so approved (the &ldquo;Continuing
Directors&rdquo;) shall cease for any reason to constitute a majority of the members of the Board; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><U>provided further</U>
that in each of the foregoing cases, the Change of Control also meets all of the requirements of a &ldquo;change in the ownership
of a corporation&rdquo; within the meaning of Treasury Regulation &sect;1.409A-3(i)(5)(v), a &ldquo;change in the effective control
of a corporation&rdquo; within the meaning of Treasury Regulation &sect;1.409A-3(i)(5)(vi) or a &ldquo;a change in the ownership
of a substantial portion of the corporation&rsquo;s assets&rdquo; within in the meaning of Treasury Regulation &sect;1.409A-3(i)(5)(vii).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>


<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Termination
Without Cause</U>. In the event of termination of the Executive&rsquo;s employment hereunder by Company &ldquo;Without Cause&rdquo;
(other than for a Termination for a Change of Control hereinafter separately provided for) the Executive shall be entitled to the
following severance pay and benefits:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Severance
Pay</I> - severance payments in the form of continuation of the Executive&rsquo;s base salary as in effect immediately prior to
such termination for a period of twelve (12) months following the effective date of such termination;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Benefits
Continuation</I> &ndash; continued coverage under the Company&rsquo;s private medical care and life insurance benefit plans in
which the Executive is participating at the time of termination, or equivalent coverage thereof, on the same terms as applicable
to other executive employees of the Company from time to time, over the same period with respect to which the Executive&rsquo;s
base salary is continued as provided in <U>Section 9(b)(i)</U> hereof; <U>provided</U>, <U>however</U>, that the Company&rsquo;s
obligation to provide such coverages shall be terminated if the Executive obtains substitute coverage from another employer of
the Executive at any time during the continuation period; the Executive shall be obligated to notify the Company of any such substitute
coverage and the date of commencement thereof promptly upon obtaining any such coverage; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Stock
Options</I> - all options to purchase shares of the Company&rsquo;s common stock held by the Executive and which are vested immediately
prior to termination of employment shall become exercisable for a period of six months following the effective date of termination
of employment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Termination
following Change in Control</U>. In the event of termination of the Executive&rsquo;s employment within six months following a
Change of Control the Executive shall be entitled to the following severance pay and benefits:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Severance
Pay</I> - Severance payments in the form of continuation as the Executive&rsquo;s base salary as in effect immediately prior to
such termination for a period of twelve (12) months following the effective date of termination;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Benefits
Continuation</I> &ndash; continued coverage under the Company&rsquo;s private medical care and life insurance benefit plans in
which the Executive is participating at the time of termination, or equivalent coverage thereof, on the same terms as applicable
to other executive employees of the Company from time to time, over the same period with respect to which the Executive&rsquo;s
base salary is continued as provided in <U>Section 9(c)(i)</U> hereof; <U>provided</U>, <U>however</U>, that the Company&rsquo;s
obligation to provide such coverages shall be terminated if the Executive obtains substitute coverage from another employer of
the Executive at any time during the continuation period; the Executive shall be obligated to notify the Company of any such substitute
coverage and the date of commencement thereof promptly upon obtaining any such coverage; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Stock
Options</I> - all options to purchase shares of the Company&rsquo;s common stock held by the Executive shall be vested and be exercisable
for a period of 18 months following the effective date of termination.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(iv)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>280G
Excise Tax</I> - it is the intention of Executive and the Company that no payments made or benefits provided by the Company to
or for the benefit of Executive under this Agreement or any other agreement or plan pursuant to which Executive is entitled to
receive payments or benefits shall be subject to the excise tax imposed on the Executive by Section 4999 of the Code (the &ldquo;280G
Excise Tax&rdquo;), relating to golden parachute payments. The Company agrees that in the event any payments to Executive pursuant
to this Agreement would result in a payment to Executive that would trigger any 280G Excise Tax, if appropriate and permissible,
the Company shall submit to its stockholders for approval the transaction that may result in the imposition of the 280G Excise
Tax upon Executive in accordance with the regulations of the Internal Revenue Code governing shareholder approval of transactions
giving rise to 280G Excise Tax liability.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Termination
Upon Disability or Death</U>. In the event of termination of the Executive&rsquo;s employment hereunder on account of the Executive&rsquo;s
&ldquo;Disability&rdquo; or death, the Executive or the Executive&rsquo;s heirs, estate or personal representatives under law,
as applicable, shall be entitled to the following severance pay and benefits:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Severance
Pay</I> - severance payments in the form of continuation of the Executive&rsquo;s base salary as in effect immediately prior to
such termination for a period of 12 months following the First Date of Disability, reduced by the amounts of any payments received
from any long-term disability plan of the Company;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Benefits
Continuation</I> - the same benefits as provided in <U>Section 9(c)(ii)</U> above, to be provided during the Employment Period
while the Executive is suffering from Disability and for a period of twelve (12) months following the effective date of termination
of employment by reason of Disability; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Stock
Options</I> - all options to purchase shares of the Company&rsquo;s common stock held by the Executive which are exercisable immediately
prior to termination of employment shall remain exercisable for a period of twelve (12) months following the effective date of
termination of employment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Other
Terminations</U>. In the event of termination of the Executive&rsquo;s employment hereunder for any reason other than those specified
in subsections (b) through (d) of this <U>Section 9</U>, the Executive shall not be entitled to any severance pay, benefits continuation
or stock option rights contemplated by the foregoing provisions of this <U>Section 9</U>, except as otherwise provided in the applicable
benefit plans of the Company that cover the Executive.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Accrued
Rights</U>. Notwithstanding the foregoing provisions of this <U>Section&nbsp;9</U>, in the event of termination of the Executive&rsquo;s
employment hereunder for any reason, the Executive shall be entitled to payment of any unpaid portion of his base salary, computed
on a pro-rata basis through the effective date of termination, and payment of any accrued but unpaid rights in accordance with
the terms of any incentive bonus or employee benefit plan or program of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>


<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(g)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Conditions
to Severance Benefits</U>. (i) As conditions of the Executive&rsquo;s entitlement and continued entitlement to the severance payments
and benefits provided by this <U>Section 9</U>, the Executive is required to (i) honor in accordance with their terms the provisions
of <U>Sections 10, 11 and 12</U> hereof and (ii) execute and honor the terms of a waiver and release of claims against the Company
substantially in the form attached hereto as <U>Exhibit A</U> (as may be modified consistent with the purposes of such waiver and
release to reflect changes in law following the date hereof) and compromise agreement in the form attached hereto as <U>Exhibit
B</U> (as may be modified consistent with the purposes of such compromise agreement to reflect changes in law following the date
hereof). The parties hereto agree that the Executive is under no affirmative obligation to seek to mitigate or offset the severance
payments and benefits provided by this <U>Section 9</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;For
purposes only of this Section, the Executive shall be treated as having failed to honor the provisions of <U>Sections 10, 11 or
12</U> hereof only upon the passing of a resolution by a majority of the Board making such a determination following notice of
the alleged failure by Company to the Executive, an opportunity for the Executive to cure the alleged failure for a period of thirty
(30) days from the date of such notice and the Executive&rsquo;s opportunity to be heard on the issue by the Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Stock
Options</I> - Notwithstanding any other provisions of this Agreement to the contrary, in the event that the Executive continues
to serve as a member of the Board following his termination of employment from Company, his rights with respect to the vesting
and exercisability of the options shall continue in the same manner as other non-executive members of the Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">10.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Confidentiality</U>.</B>
The Executive agrees that he will not at any time during the term hereof or thereafter for any reason, in any fashion, form or
manner, either directly or indirectly, divulge, disclose or communicate to any person, firm, corporation or other business entity,
in any manner whatsoever, any confidential information or trade secrets concerning the business of the Company (including the business
of any unit thereof), including, without limiting the generality of the foregoing, the names of any of its customers, the prices
at which it obtains or has obtained any products or services, the techniques, methods or systems of its operation or management,
any customer proposals or other business opportunities, any information regarding its financial matters, or any other material
information concerning the business of the Company, its manner of operation, its plans or other material data. The provisions of
this paragraph shall not apply to (i) information disclosed in the performance of the Executive&rsquo;s duties to the Company based
on his good faith belief that such a disclosure is in the best interests of the Company; (ii) information that is public knowledge;
(iii) information disseminated by the Company to others in the ordinary course of the Company&rsquo;s business, in order to further
such business, provided the recipient of such information agrees to be subject to a confidentiality obligation at least comparable
to that herein; (iv) information or knowledge lawfully received by the Executive from a third party who, based upon due inquiry
by the Executive, is not bound by a confidential relationship to the Company; or (v) information disclosed under a requirement
of law or as directed by applicable legal authority having jurisdiction over the Executive.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">11.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Inventions</U>.</B>
(i) To the extent that any of the Company&rsquo;s current or future products or services relate to, embody or incorporate concepts,
technology or products of any kind relevant to the Company or its subsidiaries or affiliates that the Executive directly or indirectly
conceived or developed prior to the date hereof during the period of his employment by Company (&ldquo;Prior Technology&rdquo;),
the Executive assigns in perpetuity to Company any and all of his rights, title and interests, if any, to utilize, without any
cost to the Company, such Prior Technology, and the Executive agrees to assist Company in taking all action that may be reasonably
required, at the Company&rsquo;s expense, to secure for the Company the benefits of the Executive&rsquo;s ownership or rights,
if any, to use all such Prior Technology.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Executive is hereby retained in a capacity such that the Executive&rsquo;s responsibilities include the making of technical, managerial
and promotional contributions of value to the Company. The Executive hereby assigns to Company all rights, title and interest in
such contributions and inventions made or conceived by the Executive alone or jointly with others which relate to the business
of the Company. This assignment shall include (a) the right to file and prosecute patent applications on such inventions in any
and all countries, (b) the patent applications filed and patents issuing thereon, and (c) the right to obtain copyright, trademark
or trade name protection for any such work product. The Executive shall promptly and fully disclose all such contributions and
inventions to the Company and assist the Company in obtaining and protecting the rights therein (including patents thereon), in
any and all countries; provided, however, that said contributions and inventions will be the property of the Company, whether or
not patented or registered for copyright, trademark or trade name protection, as the case may be. Inventions conceived by the Executive
which are not related to the business of the Company (as determined in good faith by the Board), will remain the property of the
Executive.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">12.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Non-Competition</U>.</B>
(i) the Executive agrees that he shall not during the Employment Period and for a period of one year after the termination or end
thereof for any reason, without the approval of the Board which, after the end of the Employment Period, shall not unreasonably
be withheld or delayed, directly or indirectly, alone or as partner, joint venturer, officer, director, employee, consultant, agent,
independent contractor or controlling stockholder (other than as provided below) of any Company or business, engage in any &ldquo;Competitive
Business&rdquo; within the United States or within the United Kingdom and which directly competes with the business of the Company
and/or Cyclacel Limited. For purposes of the foregoing, the term &ldquo;Competitive Business&rdquo; shall mean any business involved
in the research, development, or sale of anticancer targeted therapeutics that are nucleoside analogues, CDK inhibitors or Aurora/VEGFR2
inhibitors and/or medicines for the treatment of radiation dermatitis or xerostomia or any other business in which the Company
has been engaged up to and until the relevant time (as determined by the Board of Directors); provided that, this provision shall
in no way prevent the Executive, after the end of the Employment Period, from being employed as a consultant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>


<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Notwithstanding
the provisions of clause (i) above or any other provision of this Agreement to the contrary, the Executive shall not be prohibited
during the period applicable under clause (i) above from acting as a passive investor where (a) in the case of a Competitive Business
being a public corporation, the Executive owns not more than five percent (5%) of the issued and outstanding capital stock or such
higher percentage or amount as may be approved by the Board upon notice from the Executive prior to obtaining such interest; provided,
however, that the Executive shall not be treated as having violated the provisions of this <U>Section&nbsp;12</U> if in good faith
he is unaware that an entity in which he has an investment interest would be treated as a Competitive Business and, upon becoming
aware of such involvement, the Executive makes reasonable efforts to divest himself of his interest in such business; (b) in the
case of any employer or entity other than a Competitive Business that is engaged in, or whose affiliates are engaged in, the development
or marketing of products or technologies that are directly or indirectly competitive with any product or technology that is developed
or marketed or proposed to be developed or marketed by Company during the Employment Period, the Executive owns not more than five
percent (5%) of the issued and outstanding capital stock; or (c) receiving stock, options or warrants from any entity with which
the Executive can have a relationship pursuant to clause (i) above as part of the Executive&rsquo;s compensation for services rendered
or to be rendered.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">13.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Breach
of Restrictive Covenants</U>.</B> The parties agree that a breach or violation of <U>Sections 10, 11 or 12</U> hereof will result
in immediate and irreparable injury and harm to the innocent party, who shall have, in addition to any and all remedies of law
and other consequences under this Agreement, the right to an injunction, specific performance or other equitable relief to prevent
the violation of the obligations hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">14.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Non-Disparagement</U></B>.
The Executive agrees that he will not, whether during his provision of services to the Company or thereafter, directly or indirectly,
make, cause to be made, or ratify any statement, public or private, oral or written, to any person that disparages, either professionally
or personally, the Company or any of its affiliates, past and present, and each of them, as well as its and their trustees, directors,
officers, agents, attorneys, insurers, employees, stockholders, representatives, assigns, and successors, past and present, and
each of them.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">15.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Notices</U>.</B>
Any notice required to be given pursuant to the provisions of this Agreement shall be in writing and, if mailed, sent by registered
mail, postage prepaid, to the party named at the address set forth below, or at such other address as each party may hereafter
designate in writing to the other party:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.5in; text-indent: -1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 1in">Company:</TD><TD>200 Connell Drive #1500<BR>
Berkeley Heights, NJ 07922<BR>
Attention: Chairman of the Board</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.5in; text-indent: -1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.5in; text-indent: -1in">with a copy to (which copy will
not constitute notice):<BR>
<BR>
Mintz Levin Cohn Ferris Glovsky &amp; Popeo, P.C.<BR>
666 Third Avenue<BR>
New York, New York 10017<BR>
Attention: Joel Papernik, Esq.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.5in; text-indent: -1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 1in">Executive:</TD><TD>c/o Cyclacel Pharmaceuticals, Inc.<BR>
200 Connell Drive #1500<BR>
Berkeley Heights, NJ 07922</TD></TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.5in; text-indent: -1in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.5in; text-indent: -1in">&nbsp;</P>


<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Any such notices shall be deemed to have
been delivered when served personally in the manner specified above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">16.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Dispute
Resolution</U>.</B> The parties shall waive trial by jury in any dispute between them.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">17.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Entire
Agreement</U>.</B> (a) <I>Change, Modification, Waiver</I>. No change or modification of this Agreement shall be valid unless it
is in writing and signed by each of the parties hereto. No waiver of any provision of this Agreement shall be valid unless it is
in writing and signed by the party against whom the waiver is sought to be enforced. The failure of a party to insist upon strict
performance of any provision of this Agreement in any one or more instances shall not be construed as a waiver or relinquishment
of the right to insist upon strict compliance with such provision in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Integration
of All Agreements</I>. This Agreement constitutes the entire Agreement between the parties and is intended to be an integration
of all agreements between the parties with respect to the Executive&rsquo;s service with Company. Except as provided in <U>Section
8</U> hereof concerning the Indemnification Agreement, any and all prior agreements between the Executive and the Company with
respect to the Executive&rsquo;s service with the Company are hereby revoked.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Severability
of Provisions</I>. If for any reason any provision of this Agreement should be declared void or invalid, such declaration shall
not affect the validity of the rest of this Agreement, which shall remain in force as if executed with the void or invalid provision
eliminated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">18.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Binding
Effect</U>.</B> This Agreement shall be binding upon all parties hereto and their heirs, successors and assigns. This Agreement
shall be assignable by Company to any entity acquiring all or substantially all of the assets of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">19.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Governing
Law</U>.</B> This Agreement shall be governed by and construed in accordance with the laws of the State of New Jersey, except that,
and only to the extent applicable, England law shall govern the working conditions and the like.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">20.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Miscellaneous</U>.</B>
(a) <I>Form</I>. As employed in this Agreement, the singular form shall include, if appropriate, the plural.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Headings</I>.
The headings employed in this Agreement are solely for the convenience and reference of the parties and are not intended to be
descriptive of the entire contents of any paragraph and shall not limit or otherwise affect any of terms, provisions, or construction
thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>


<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Modifications</I>.
Notwithstanding any other provision with respect to the timing of payments under this Agreement, if, at the time of Executive&rsquo;s
expiration of the Employment Period, the non-renewal of the Executive&rsquo;s employment is deemed to be dismissal or termination
(within the meaning of the UK law or any other applicable law), limited only to the extent necessary to comply with the requirements
of the UK law, any payment to which Executive may become entitled under the UK law will be withheld, but no later than the first
(1st) business day of the 11th week following the expiration of the Employment Period, at which time the parties to this Agreement
will be negotiate in good faith a mechanism effective under the UK law to carry out the intent and purpose of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">21.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Additional
Terms of Statement of Main Terms and Conditions of Employment</U>.</B> The parties shall execute and deliver a Statement of Main
Terms and Conditions of Employment as required by UK law and conforming, to the extent practicable, with the terms and conditions
of the foregoing .</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><I>[signature page follows]</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>


<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><B>IN WITNESS WHEREOF,</B>
this Agreement is executed as of the date first above written.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3"><FONT STYLE="text-transform: uppercase"><B>Cyclacel Pharmaceuticals, Inc.</B></FONT><B>:</B></TD>
    </TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD>
    </TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid">&nbsp;</TD>
    </TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD>
    </TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD>
    </TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>By:</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid">&nbsp;</TD>
    </TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 5%">Name:</TD>
    <TD STYLE="width: 42%; border-bottom: Black 1pt solid">&nbsp;</TD>
    </TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Title:</TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD>
    </TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD>
    </TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3"><FONT STYLE="text-transform: uppercase"><B>Paul McBarron</B></FONT><B>:</B></TD>
    </TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD>
    </TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid">&nbsp;</TD>
    </TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in">&nbsp;</P>


<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B><I>EXECUTION COPY</I></B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>Exhibit A</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Waiver and Release</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><B>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Your
Release of Claims.</U></B> You hereby agree and acknowledge that by signing this Agreement, and for other good and valuable consideration,
you are waiving your right to assert any and all forms of legal claims against the Company<SUP>1/</SUP> of any kind whatsoever,
whether known or unknown, arising from the beginning of time through the date you execute this Agreement (the &ldquo;Execution
Date&rdquo;). Except as set forth below, your waiver and release herein is intended to bar any form of legal claim, complaint or
any other form of action (jointly referred to as &ldquo;Claims&rdquo;) against the Company seeking any form of relief including,
without limitation, equitable relief (whether declaratory, injunctive or otherwise), the recovery of any damages, or any other
form of monetary recovery whatsoever (including, without limitation, back pay, front pay, compensatory damages, emotional distress
damages, punitive damages, attorneys fees and any other costs) against the Company, for any alleged action, inaction or circumstance
existing or arising through the Execution Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Without limiting the foregoing general waiver
and release, you specifically waive and release the Company from any Claim arising from or related to your prior employment relationship
with the Company or the termination thereof, including, without limitation:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">**</TD><TD STYLE="text-align: justify">Claims under any state or federal discrimination, fair employment practices or other employment related statute, regulation
or executive order (as they may have been amended through the Execution Date) prohibiting discrimination or harassment based upon
any protected status including, without limitation, race, national origin, age, gender, marital status, disability, veteran status
or sexual orientation. Without limitation, specifically included in this paragraph are any Claims arising under the Age Discrimination
in Employment Act, Title VII of the Civil Rights Act of 1964, the Civil Rights Act of 1991, the Americans With Disabilities Act
and any similar Federal and state statute.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">**</TD><TD STYLE="text-align: justify">Claims under any other state or federal employment related statute, regulation or executive order (as they may have been amended
through the Execution Date) relating to wages, hours or any other terms and conditions of employment.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">**</TD><TD STYLE="text-align: justify">Claims under any state or federal common law theory including, without limitation, wrongful discharge, breach of express or
implied contract, promissory estoppel, unjust enrichment, breach of a covenant of good faith and fair dealing, violation of public
policy, defamation, interference with contractual relations, intentional or negligent infliction of emotional distress, invasion
of privacy, misrepresentation, deceit, fraud or negligence.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: left; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: left; margin-bottom: 0pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">**</TD><TD>Any other Claim arising under state or federal law.</TD></TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: left; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: left; margin-bottom: 0pt">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 25%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: left; margin-bottom: 0pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.3in"><SUP>1/</SUP></TD><TD STYLE="text-align: justify">For purposes of this Agreement, the Company includes the Company and any of its divisions, affiliates
(which means all persons and entities directly or indirectly controlling, controlled by or under common control with the Company),
subsidiaries and all other related entities, and its and their directors, officers, employees, trustees, agents, successors and
assigns.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 14; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">Notwithstanding the foregoing, nothing contained
in this Release constitutes a waiver of any Claims you may have against the Company arising from or related to the Indemnification
Agreement and By-laws provisions referenced in Section 8 of the Employment Agreement, dated January 1, 2014, entered into between
you and the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">You acknowledge and agree that, but for
providing this waiver and release, you would not be receiving the economic benefits being provided to you under the terms of this
Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><B>It is the Company&rsquo;s desire and
intent to make certain that you fully understand the provisions and effects of this Agreement. To that end, you have been encouraged
and given the opportunity to consult with legal counsel for the purpose of reviewing the terms of this Agreement. Also, because
you are over the age of 40 and consistent with the provisions of the Age Discrimination in Employment Act (&ldquo;ADEA&rdquo;),
which prohibits discrimination on the basis of age, the Company is providing you with twenty-one (21) days in which to consider
and accept the terms of this Agreement by signing below and returning it to me at: [name], [address].</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><B>You may rescind your assent to this Agreement
if, within seven (7) days after you sign this Agreement, you deliver by hand or send by mail (certified, return receipt and postmarked
within such 7 day period) a notice of rescission to me at the Company. The eighth day following your signing of this Agreement
is the Effective Date.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">Also, consistent with the provisions of
Federal and state discrimination laws, nothing in this release shall be deemed to prohibit you from challenging the validity of
this release under such discrimination laws (the &ldquo; Discrimination Laws&rdquo;) or from filing a charge or complaint of age
or other employment related discrimination with the Equal Employment Opportunity Commission (&ldquo;EEOC&rdquo;) or state equivalent,
or from participating in any investigation or proceeding conducted by the EEOC or state equivalent. Further, nothing in this release
or Agreement shall be deemed to limit the Company&rsquo;s right to seek immediate dismissal of such charge or complaint on the
basis that your signing of this Agreement constitutes a full release of any individual rights under the Discrimination Laws, or
to seek restitution to the extent permitted by law of the economic benefits provided to you under this Agreement in the event that
you successfully challenge the validity of this release and prevail in any claim under the Discrimination Laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 7%">By: </TD>
    <TD STYLE="width: 43%; border-bottom: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-left: 0.125in">Paul McBarron</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 12%">Date signed: </TD>
    <TD STYLE="width: 38%; border-bottom: Black 1pt solid">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in">&nbsp;</P>


<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in"><U STYLE="text-decoration: none">&nbsp;</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><U>Exhibit B</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><U>Compromise Agreement</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 220.5pt; text-align: center; text-indent: -220.5pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>COMPROMISE
AGREEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 220.5pt; text-align: center; text-indent: -220.5pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">THIS COMPROMISE AGREEMENT (the &ldquo;<B>Agreement</B>&rdquo;)
is made as of [<FONT STYLE="font-family: Times New Roman, Times, Serif">&bull;</FONT>] by and between Cyclacel Pharmaceuticals,
Inc. (the &ldquo;<B>Employer</B>&rdquo;) and Paul McBarron (the &ldquo;<B>Executive</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 220.5pt; text-indent: -220.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">WHEREAS, the Employer has employed the
Executive as Executive Vice President, Finance, Chief Financial Officer, Chief Operating Officer and Secretary since [<FONT STYLE="font-family: Times New Roman, Times, Serif">&bull;</FONT>];
and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">WHEREAS, the Executive may have certain
claims against the Employer in respect of the Executive&rsquo;s employment during the period of the Executive&rsquo;s employment
with the Employer and up to the date of signing of this Agreement by the parties, and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">WHEREAS, without admitting the validity
of all or any of these claims, the Employer wishes to settle with the Executive;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">NOW THEREFORE THE PARTIES AGREE AS FOLLOWS:-</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left">1.</TD><TD STYLE="text-align: justify"><U>Claims against the Employer</U></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">a.</TD><TD STYLE="text-align: justify">The Executive asserts that the Executive may have the following
particular claims (the &ldquo;<B>Asserted Claims</B>&rdquo;), and no other claims, against the Employer, its directors, officers
or employees, or against any associated company or person, or any affiliates of the Employer (collectively, the &ldquo;<B>Affiliates</B>&rdquo;)
arising from the Executive&rsquo;s employment with the Employer or the termination thereof:</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">i.</TD><TD STYLE="text-align: justify">Any claim for damages for breach of contract for notice
or pay in lieu of notice;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">ii.</TD><TD STYLE="text-align: justify">Any claim for holiday pay; or payment of an accrued untaken
holiday entitlement;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">iii.</TD><TD STYLE="text-align: justify">Any claim for outstanding pay, overtime, expenses, ex-gratia
or discretionary payments, use of Company vehicle, Directors&rsquo; fees, bonuses or commission and also including a claim under
the Equal Pay Act 1970 or Article 119 of the Treaty of Rome (as amended by the Treaty of Amsterdam);</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">iv.</TD><TD STYLE="text-align: justify">A claim by the Executive for breach of contract by the
Employer;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">v.</TD><TD STYLE="text-align: justify">Any claim for unfair dismissal; or unfair constructive
dismissal;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">vi.</TD><TD STYLE="text-align: justify">Any claim for unlawful deduction from wages under Part
II of the Employment Rights Act 1996;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 16; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">B-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">vii.</TD><TD STYLE="text-align: justify">Any claim for redundancy payment whether statutory or otherwise;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">viii.</TD><TD STYLE="text-align: justify">Any claim for a failure to follow the statutory dispute
resolution procedures under the Employment Act 2002 and the Employment Act 2002 (Dispute Resolution) Regulations 2004;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">ix.</TD><TD STYLE="text-align: justify">Any claim for breach of the Working Time Regulations 1998
including non-payment of holiday pay;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">x.</TD><TD STYLE="text-align: justify">Any claim for failure to give a Statement of Main Terms
and Conditions of Employment or dispute resolution procedures in terms of Part I of the Employment Rights Act 1996;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">b.</TD><TD STYLE="text-align: justify">The Executive confirms that the Executive&rsquo;s only
claims or complaints against the Employer or Affiliates are the Asserted Claims and that the Executive is aware of no other claim
or grounds to make a claim against the Employer or Affiliates in relation to any other matters howsoever arising.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">c.</TD><TD STYLE="text-align: justify">The Executive accepts the terms of this Agreement in full
and final settlement of the Asserted Claims and all other claims, complaints, costs, expenses or rights of action of any kind,
present, future or contingent, which the Executive may have against the Employer or Affiliates, whether under statute, contract
or at common law or under legislation or directives of the European Union, arising from the Executive&rsquo;s employment with
the Employer or the termination thereof, including, but not limited to:</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">i.</TD><TD STYLE="text-align: justify">Any claim for sex discrimination or victimisation, or harassment
under the Sex Discrimination Act 1975;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">ii.</TD><TD STYLE="text-align: justify">Any claim for race discrimination or victimisation, or
harassment under the Race Relations Act 1976;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">iii.</TD><TD STYLE="text-align: justify">Any claim for disability discrimination or victimisation
or harassment under the Disability Discrimination Act 1995;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">iv.</TD><TD STYLE="text-align: justify">Any claim for discrimination, victimisation or harassment
under the Employment Equality (Sexual Orientation) Regulations 2003;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">v.</TD><TD STYLE="text-align: justify">Any claim for discrimination, victimisation or harassment
under the Employment Equality (Religion or Belief) Regulations 2003;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">vi.</TD><TD STYLE="text-align: justify">Any claim for discrimination, victimisation or harassment
under the Employment Equality (Age) Regulations 2006;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 17; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">B-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">vii.</TD><TD STYLE="text-align: justify">Any claim for less favourable treatment, detriment, unfair
dismissal or victimisation under the Part Time Workers (Prevention of Less Favourable Treatment) Regulations 2000;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">viii.</TD><TD STYLE="text-align: justify">Any claim for less favourable treatment, detriment, unfair
dismissal or victimisation under the Fixed Term Executives (Prevention of Less Favourable Treatment) Regulations 2002;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">ix.</TD><TD STYLE="text-align: justify">Any claim under the National Minimum Wage Act 1998;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">x.</TD><TD STYLE="text-align: justify">Any claim in relation to trade union membership, unfair
dismissal or detriment on the grounds they are a trade union member under the Trade Union and Labour Relations (Consolidation)
Act 1992;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">xi.</TD><TD STYLE="text-align: justify">Any claim for a protective award under Trade Union and
Labour Relations (Consolidation) Act 1992;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">xii.</TD><TD STYLE="text-align: justify">Any claim for harassment under the Protection from Harassment
Act 1997;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">xiii.</TD><TD STYLE="text-align: justify">Any claim under Part VII of the Transnational Information
and Consultation of Executives Regulations 1999;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">xiv.</TD><TD STYLE="text-align: justify">Any claim for compensation under the Data Protection Act
1998;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">xv.</TD><TD STYLE="text-align: justify">Any claim under Part VIII of the Information and Consultation
of Executives Regulations 2004;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">xvi.</TD><TD STYLE="text-align: justify">Any claim for a protective award under the Transfer of
Undertakings (Protection of Employment) Regulations 2006;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">xvii.</TD><TD STYLE="text-align: justify">Any claim for a guarantee payment in terms of Part III
of the Employment Rights Act 1996;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">xviii.</TD><TD STYLE="text-align: justify">Any claim by the Executive that they have suffered a detriment
on the grounds of provisions relating to:</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in; text-align: left">(a)</TD><TD STYLE="text-align: justify">health and safety;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in; text-align: left">(b)</TD><TD STYLE="text-align: justify">Sunday working;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in; text-align: left">(c)</TD><TD STYLE="text-align: justify">the Working Time Regulations 1998;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in; text-align: left">(d)</TD><TD STYLE="text-align: justify">undertaking duties of an Occupational Pension Scheme Trustee;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in; text-align: left">(e)</TD><TD STYLE="text-align: justify">undertaking duties as an Executive representative;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in; text-align: left">(f)</TD><TD STYLE="text-align: justify">time off work for study or training;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in; text-align: left">(g)</TD><TD STYLE="text-align: justify">protected disclosures;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in; text-align: left">(h)</TD><TD STYLE="text-align: justify">family leave;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in; text-align: left">(i)</TD><TD STYLE="text-align: justify">dependant leave;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in; text-align: left">(j)</TD><TD STYLE="text-align: justify">flexible working;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 18; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">B-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in; text-align: left">(k)</TD><TD STYLE="text-align: justify">enforcing or securing the benefit of or right conferred
under the Tax Credits Act 2002.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">all in terms of Sections 44
to 48 of the Employment Rights Act 1996;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">xix.</TD><TD STYLE="text-align: justify">Any claim for compensation under Section 80H of the Employment
Rights Act 1996 (flexible working), but excluding any claims in relation to accrued pension rights or any claims for damages for
personal injuries, in respect of the latter of which the Executive warrants that the Executive is not aware of any such claims.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.75in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">d.</TD><TD STYLE="text-align: justify">The Executive warrants that, at the date of this Agreement,
the Executive has not issued any proceedings against the Employer or Affiliates, whether in an Employment Tribunal or otherwise,
and agrees to withdraw any such proceedings instituted on their behalf.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">e.</TD><TD STYLE="text-align: justify">If the waiver of the Asserted Claims or any other
claims contained in this Clause is judged to be void or unenforceable, but would be valid if any one or more of the waivers were
reduced, the waiver(s) shall be deemed to apply with such modification(s) as may be necessary to make them valid and effective.
Any such modification of any one waiver of a claim shall not affect the validity of any other waiver of claim contained in this
contract.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left">2.</TD><TD STYLE="text-align: justify"><U>Executive warranties</U></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">a.</TD><TD STYLE="text-align: justify">The Executive warrants that he is not aware of any matters
relating his employment which if disclosed to the Employer might affect the Employer&rsquo;s decision to enter into this Agreement.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">b.</TD><TD STYLE="text-align: justify">The Executive warrants that the Executive has complied
with all of his obligations to the Employer and have not done or failed to do anything which would have allowed the Employer to
terminate the Executive employment with immediate effect.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left">3.</TD><TD STYLE="text-align: justify"><U>Legal Advice</U></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">a.</TD><TD STYLE="text-align: justify">The Executive warrants to the Employer that before signing
this Agreement the Executive received independent legal advice from [&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;]
Solicitor, [&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;]
a qualified lawyer (&ldquo;The Advisor&rdquo;), as to the terms and effects of this Agreement, and, in particular, its effect
on the Executive&rsquo;s ability to pursue the Executive&rsquo;s rights before an Employment Tribunal or a Court. The Advisor
has in force a Policy of Insurance covering the risk of a claim by the Executive in respect of any loss arising in consequence
of the said legal advice.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 19; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">B-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">b.</TD><TD STYLE="text-align: justify">The Executive warrants to the Employer that the Executive
has provided the Advisor with all available information which the Advisor requires or may require to advise whether the Executive
has any claims, and in particular any of the claims listed in Clause 1 of this Agreement, against the Employer or Affiliates.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">c.</TD><TD STYLE="text-align: justify">The Executive warrants to the Employer that the Advisor
has advised the Executive that on the basis of the information available to the Advisor the Executive&rsquo;s only claims or particular
complaints against the Employer or Affiliates are the Asserted Claims and that he has no other claim against the Employer whether
statutory or otherwise.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left">4.</TD><TD STYLE="text-align: justify"><U>Compliance with statutory provisions</U></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">a.</TD><TD STYLE="text-align: justify">The Executive declares and acknowledges that the Executive
has carefully read and fully understands all of the provisions of this Agreement and voluntarily agrees to and intends to be legally
bound by all its terms and in particular the Executive acknowledges that this Agreement is a Compromise Agreement within the meaning
of s.203(2)(f) of the Employment Rights Act 1996 and that by entering into this Agreement the Executive has agreed not to institute
or continue any proceedings before an Employment Tribunal or the Courts arising out of the termination of the Executive&rsquo;s
employment.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">b.</TD><TD STYLE="text-align: justify">The Employer and the Executive agree and acknowledge that
the conditions regulating Compromise Agreements under Section 203(3) of the Employment Rights Act 1996, Section 288 of the Trade
Union and Labour Relations (Consolidation) Act 1992; Section 77(4A) of the Sex Discrimination Act 1975; Section 72(4A) of the
Race Relations Act 1976; Schedule 3A of the Disability Discrimination Act 1995 and Regulation 35(3) of the Working Time Regulations
1998, Section 49 of the National Minimum Wage Act 1998, Regulation 10 of the Fixed Term Executives (Prevention of less favourable
Treatment) Regulations 2002; Regulation 9 of the Part Time Workers (Prevention of Less favourable Treatment) Regulations 2000,
Schedule 4 of the Employment Equality (Religion or Belief) Regulations 2003, Schedule 4 of the Employment Equality (Sexual Orientation)
Regulations 2003; Schedule 5 of the Employment Equality (Age) Regulations 2006; Regulation 40 of the Information and Consultation
of Executives Regulations 2004; and Regulation 41 of the Transnational information and Consultation of Executives Regulations
1998 all as maybe re-enacted or amended are intended to be and have been satisfied and that the Executive has intimated the foregoing
claims.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">IN WITNESS
WHEREOF these presents consisting of this and the [&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;] preceding pages are executed
as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 20; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">B-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">They
are subscribed for and on behalf of the Employer at [&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;] on the
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;day
of [&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;] 20__ the presence of the following witness by:-</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; text-align: justify; border-bottom: Black 1pt solid"></TD>
    <TD STYLE="width: 50%; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">(Witness)</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: right; border-bottom: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">(Authorised Signatory)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">(Full Name)</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">(Address)</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: justify; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">(Occupation)</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">They
    are subscribed by the Executive at [&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;] on the&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    day of [&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;] 20__ in the presence of the following witness:-</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">(Witness)</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: right; border-bottom: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">[Executive&rsquo;s name]</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">(Full Name)</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">(Address)</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">(Occupation)</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 21; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">B-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">22.</TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Solicitor&rsquo;s Certificate
under Section 203 of the Employment Rights Act 1996</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">I, [&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;]
hereby certify as follows:-</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left">1.</TD><TD STYLE="text-align: justify">I am a solicitor holding a current Practising Certificate.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left">2.</TD><TD STYLE="text-align: justify">I have advised [&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Executive&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;]
of the terms and effects of the attached Agreement and in particular its effect on the Executive&rsquo;s ability to pursue a claim
to an Employment Tribunal and/or the Courts following its signing.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left">3.</TD><TD STYLE="text-align: justify">I am not acting and have not acted in relation to this
matter for [&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;employer&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;]</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left">4.</TD><TD STYLE="text-align: justify">There is in force a policy of insurance covering the risk
of a claim by the Executive in respect of loss arising in consequence of the advice I have given.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left">5.</TD><TD STYLE="text-align: justify">The conditions regulating Compromise Agreements under Section
203(3) of the Employment Rights Act 1996, Section 288 of the Trade Union and Labour Relations (Consolidation) Act 1992; Section
77(4A) of the Sex Discrimination Act 1975; Section 72(4A) of the Race Relations Act 1976; Schedule 3A of the Disability Discrimination
Act 1995 and Regulation 35(3) of the Working Time Regulations 1998, Section 49 of the National Minimum Wage Act 1998, Regulation
10 of the Fixed Term Executives (Prevention of less favourable Treatment) Regulations 2002; Regulation 9 of the Part Time Workers
(prevention of Less favourable Treatment) Regulations 2000, Schedule 4 of the Employment Equality (Religion or Belief) Regulations
2003, Schedule 4 of the Employment Equality (Sexual Orientation) Regulations 2003; Schedule 5 of the Employment Equality (Age)
Regulations 2006; Regulation 40 of the Information and Consultation of Executives Regulations 2004; and Regulation 41 of the Transnational
Information and Consultation of Executives Regulations 1998 have accordingly been satisfied.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 6%; text-align: justify"><FONT STYLE="font-size: 10pt">(Sgd.)</FONT></TD>
    <TD STYLE="width: 24%; text-align: justify; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="width: 13%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 8%; text-align: justify"><FONT STYLE="font-size: 10pt">Date</FONT></TD>
    <TD STYLE="width: 27%; text-align: justify; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="width: 22%; text-align: justify">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 22; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">B-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>4
<FILENAME>tv481140_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"><FONT STYLE="text-transform: uppercase; text-underline-style: double"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 99.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; font-size: 10pt"><IMG SRC="image_001.jpg"></TD>
    <TD STYLE="width: 50%; font-size: 10pt; text-align: right; vertical-align: middle"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cyclacel Pharmaceuticals, Inc.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="image_002.jpg"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><FONT STYLE="text-transform: uppercase"><B>Cyclacel
Announces PRESENTATION OF RESULTS FROM PHASE 3 </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><FONT STYLE="text-transform: uppercase"><B>SEAMLESS
STUDY AT ASH ANNUAL MEETING</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>Berkeley Heights, NJ, December 12,
2017</B> - Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; &quot;Cyclacel&quot; or the &quot;Company&quot;), a biopharmaceutical
company developing oral therapies that target various phases of cell cycle control for the treatment of cancer and other serious
disorders, today announced results from the Company's Phase 3 SEAMLESS study. Cyclacel had previously announced top-line results
from its Phase 3 SEAMLESS study in February 2017. The study enrolled elderly patients with newly diagnosed acute myeloid leukemia
(AML) and compared alternating cycles of decitabine and sapacitabine versus decitabine. Data were reported at an oral presentation
on Monday, December 11, at 6:45 PM EST at the 59<SUP>th</SUP> American Society of Hematology Annual Meeting in Atlanta, Georgia.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&ldquo;Although the study did not reach
its primary endpoint of superiority in survival, we are encouraged by the higher complete remission rate on the sapacitabine-decitabine
arm, especially in the subgroup with low white blood cell count; additional analysis of the data should be pursued,&rdquo; said
Hagop Kantarjian, M.D., Professor and Chair, Department of Leukemia, The University of Texas MD Anderson Cancer Center, and chair
of the study.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&quot;We are pleased to report detailed
results of the SEAMLESS study, which as previously announced, did not reach its primary endpoint,&rdquo; said Spiro Rombotis, President
and Chief Executive Officer of Cyclacel. &ldquo;We believe that the subgroup results have defined a patient population for whom
the decitabine-sapacitabine regimen may represent an improvement over low intensity treatment by decitabine alone. We plan to discuss
the data, the statistical robustness of the subgroup results and the optimal baseline peripheral white blood cell (WBC) cutpoint
with European and US regulatory authorities and will provide updates as appropriate. We are grateful to the patients, their families
and the investigators for their contributions to this large study. In parallel, we are progressing our other clinical programs
in transcriptional regulation with CYC065 and DNA damage response with sapacitabine-seliciclib in biomarker-selected patients with
solid tumors, such as those with BRCA mutations or resistance to existing cancer therapies.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>Study Design &amp; Intent-to-Treat
Results</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">The randomized, open label, Phase 3
SEAMLESS study enrolled 482 patients, aged 70 years or older, with newly diagnosed AML who were not candidates for or refused intensive
therapy at 110 US and EU sites. Patients were stratified by WBC, antecedent hematologic disorder (AHD), and marrow blasts, and
randomized 1:1 to receive either intravenous decitabine administered in alternating cycles with oral sapacitabine versus intravenous
decitabine alone.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">The trial did not meet its primary
endpoint of demonstrating statistically significant improvement in overall survival. A higher complete remission (CR) rate, a secondary
endpoint, was observed on the decitabine-sapacitabine arm (17% versus 11%). Other endpoints and safety were similar between the
arms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Wingdings">&thorn;</FONT>
<FONT STYLE="font-family: Times New Roman, Times, Serif">200 Connell Drive, Suite 1500, Berkeley Heights, NJ 07922, USA Tel +1
908 517 7330 Fax +1 866 271 3466</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Wingdings">&uml;</FONT>
<FONT STYLE="font-family: Times New Roman, Times, Serif">1 James Lindsay Place, Dundee, DD1 5JJ, UK Tel +44 1382 206 062 Fax +44
1382 206 067</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>www.cyclacel.com</U>
&ndash; <U>info@cyclacel.com</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>Prespecified Subgroup Analysis</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>Baseline WBC</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">In the less than 10,000 WBC subgroup
(n=319) a trend towards improved overall survival (median 8.0 versus 5.8 months, HR=0.84 [0.66, 1.06], p=0.14) favoring decitabine-sapacitabine
and a significantly higher CR rate (21.0% versus 8.6%, p=0.0017) was achieved on decitabine-sapacitabine.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">In the 10,000 or more WBC subgroup
(n=163) significantly better overall survival (median 3.8 versus 5.5 months, HR=1.57 [1.12, 2.19], p=0.007) was observed on decitabine.
A trend in CR rate (8.3% versus 15.2%, p=0.18) favoring decitabine was observed but it did not reach statistical significance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>Prior AHD</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">In the subgroup with prior AHD (n=136)
a significantly higher CR rate (16.7% versus 5.7%, p=0.0398) was achieved on decitabine-sapacitabine. There was a numerical difference
in median survival (6.4 versus 5.0 months, HR=0.85 [0.59, 1.24], p=0.41) favoring decitabine-sapacitabine but overall survival
did not reach statistical significance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">In the subgroup without prior AHD (n=346)
there was a numerical difference in median survival (5.9 versus 6.7 months, HR=1.08 [0.86, 1.35], p=0.52) favoring decitabine and
CR rate (16.6% versus 12.9%) favoring decitabine-sapacitabine but neither reached statistical significance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>Cytogenetics</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">In the subgroup with other than unfavorable
cytogenetics (n=288) there was a numerical difference in median survival (8.2 versus 5.7 months, HR=0.89 [0.69, 1.15], p=0.38)
and CR rate (19.9% versus 11.6%, p=0.16) favoring decitabine-sapacitabine but neither reached statistical significance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">In the subgroup with unfavorable cytogenetics
(n=194) there was a numerical difference in median survival (3.8 months versus 5.7 months, HR=1.27 [0.94, 1.73], p=0.12) favoring
decitabine but overall survival did not reach statistical significance. There was a numerical difference in CR rate favoring decitabine-sapacitabine
(12.0% versus 9.6%) but it did not reach statistical significance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">In the subgroup of patients with below
50% and with 50% or higher bone marrow blasts there were no statistically significant differences in overall survival between the
arms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>Presentation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">The presentation (abstract 891), titled
&quot;Results of a Phase 3 Study of Elderly Patients with Newly Diagnosed AML Treated with Sapacitabine and Decitabine Administered
in Alternating Cycles,&quot; is available on the Cyclacel website at www.cyclacel.com.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 2; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>About Sapacitabine</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Sapacitabine (CYC682), an orally-available
nucleoside analogue, is currently being studied in an ongoing, extension of a Phase 1 study evaluating a combination regimen of
sapacitabine and seliciclib, a first generation CDK inhibitor. Parts 1 and 2 of the study evaluated approximately 90 patients with
advanced cancers. Part 3 is ongoing in patients with BRCA positive, breast, ovarian and pancreatic cancer. Over 1,000 patients
with hematological malignancies and solid tumors have received sapacitabine.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>About AML</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">AML is a rapidly progressing cancer
of the blood characterized by the uncontrolled proliferation of immature blast cells in the bone marrow. The American Cancer Society
estimates there will be approximately 21,380 new cases of AML and approximately 10,590 deaths from AML in the U.S. in 2017. AML
is generally a disease of older adults and the median age is about 67 years. Newly diagnosed elderly patients with poor prognostic
risk factors typically die within one year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>About Cyclacel Pharmaceuticals,
Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Cyclacel Pharmaceuticals is a clinical-stage
biopharmaceutical company using cell cycle, transcriptional regulation and DNA damage response biology to develop innovative, targeted
medicines for cancer and other proliferative diseases. Cyclacel's transcriptional regulation program is evaluating CYC065, a CDK
inhibitor, in patients with advanced cancers. The DNA damage response program is evaluating a sequential regimen of sapacitabine
and seliciclib, a CDK inhibitor, in patients with BRCA positive, advanced solid cancers. Cyclacel's strategy is to build a diversified
biopharmaceutical business focused in hematology and oncology based on a pipeline of novel drug candidates. For additional information,
please visit www.cyclacel.com.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>Forward-looking Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">This news release contains certain
forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from
historical results or from any future results expressed or implied by such forward-looking statements. Such forward-looking statements
include statements regarding, among other things, the efficacy, safety and intended utilization of Cyclacel's product candidates,
the conduct and results of future clinical trials, plans regarding regulatory filings, future research and clinical trials and
plans regarding partnering activities. Factors that may cause actual results to differ materially include the risk that product
candidates that appeared promising in early research and clinical trials do not demonstrate safety and/or efficacy in larger-scale
or later clinical trials, trials may have difficulty enrolling, Cyclacel may not obtain approval to market its product candidates,
the risks associated with reliance on outside financing to meet capital requirements, and the risks associated with reliance on
collaborative partners for further clinical trials, development and commercialization of product candidates. You are urged to consider
statements that include the words &quot;may,&quot; &quot;will,&quot; &quot;would,&quot; &quot;could,&quot; &quot;should,&quot;
&quot;believes,&quot; &quot;estimates,&quot; &quot;projects,&quot; &quot;potential,&quot; &quot;expects,&quot; &quot;plans,&quot;
&quot;anticipates,&quot; &quot;intends,&quot; &quot;continues,&quot; &quot;forecast,&quot; &quot;designed,&quot; &quot;goal,&quot;
or the negative of those words or other comparable words to be uncertain and forward-looking. For a further list and description
of the risks and uncertainties the Company faces, please refer to our most recent Annual Report on Form 10-K and other periodic
and other filings we file with the Securities and Exchange Commission and are available at <FONT>www.sec.gov</FONT>.
Such forward-looking statements are current only as of the date they are made, and we assume no obligation to update any forward-looking
statements, whether as a result of new information, future events or otherwise.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Contacts</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 2in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Company:</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Paul
                                         McBarron, (908) 517-7330, <U>pmcbarron@cyclacel.com</U></FONT></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 2in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Investor&nbsp;Relations:</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Russo
                                         Partners LLC, Alexander Fudukidis, (646) 942-5632,</FONT><BR>
                                         <FONT STYLE="font-family: Times New Roman, Times, Serif"><U>alex.fudukidis@russopartnersllc.com</U></FONT></TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@ 1 "U P$1  (1 0,1 ?_$ *4  0 !!0$! 0
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M?N@6-X#NT $G13J"E3TQED6HY?QQ0<L4"52G:+DVF5B_TV:1^B4K5[A"LK!
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MC<6296F_$.>G:0D'X>'PJUL+PA%]#?6$<?']KKNT.*G5@(^,D1'R&N&4(/\
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#K__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>image_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_002.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@ %P), P$1  (1 0,1 ?_$ '(  0 # 0 " P
M       '" D& P4! @H! 0                     0   % P0!! $# P,%
M      $" P0%  8'U!=7EQ$A$A,(,4$B%",5"5$R4K)S-"46$0$
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MO^ZX^YKMM%*W[<=QDLE'B()Q!G[UNO(MFQTE%""HD8BH H(^?(!06GH% H%
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%-70?_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
